

# CITATION REPORT

List of articles citing

## The Schedule for the Deficit syndrome: an instrument for research in schizophrenia

DOI: 10.1016/0165-1781(89)90153-4  
Psychiatry Research, 1989, 30, 119-23.

**Source:** <https://exaly.com/paper-pdf/20849175/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
681	Anhedonia and the deficit syndrome of schizophrenia. <i>Psychiatry Research</i> , <b>1990</b> , 31, 25-30	9.9	98
680	Deficit syndrome in older schizophrenic patients. <i>Psychiatry Research</i> , <b>1991</b> , 39, 285-92	9.9	25
679	Psychopathology and common sense. <b>1991</b> , 29, 735-7		23
678	Negative symptoms, defect state and Huber's basic symptoms: a comparison of the concepts. <b>1991</b> , 62, 277-98		5
677	Assessment of enduring deficit and negative symptom subtypes in schizophrenia. <i>Schizophrenia Bulletin</i> , <b>1991</b> , 17, 565-82	1.3	106
676	Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alterations with deficit syndrome. <b>1992</b> , 49, 522-30		439
675	The negative symptom challenge. <b>1992</b> , 49, 236-7		26
674	Positive and negative symptoms in schizophrenia: where are the data?. <b>1992</b> , 31, 431-4		18
673	Case identification and stability of the deficit syndrome of schizophrenia. <i>Psychiatry Research</i> , <b>1993</b> , 47, 47-56	9.9	142
672	Strong inference, theory testing, and the neuroanatomy of schizophrenia. <b>1993</b> , 50, 825-31		113
671	Neuropsychological impairments in deficit vs nondéficit forms of schizophrenia. <b>1994</b> , 51, 804-11		200
670	Negative symptoms in schizophrenia: considerations for clinical trials. Working group on negative symptoms in schizophrenia. <b>1994</b> , 115, 221-8		63
669	A comparison of plasma homovanillic acid in the deficit and nondéficit subtypes of schizophrenia. <b>1994</b> , 36, 230-6		39
668	Psychiatric disease and the neurobiology of social behavior. <b>1994</b> , 36, 501-2		5
667	Persisting negative symptoms and information-processing deficits in schizophrenia: implications for subtyping. <i>Psychiatry Research</i> , <b>1994</b> , 54, 59-69	9.9	9
666	Subtypes of negative symptoms: the primary subtype in schizophrenic and non-schizophrenic patients. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>1994</b> , 18, 311-20	5.5	11
665	Positive versus negative symptoms in schizophrenia: response to haloperidol. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>1994</b> , 18, 155-64	5.5	10

664	Neuroleptics and the neuroleptic-induced deficit syndrome. <b>1994</b> , 380, 8-13		69
663	Deficit symptoms in schizophrenia: negative symptoms versus neuroleptic-induced deficits. <b>1994</b> , 380, 21-6		29
662	Syndromes of schizophrenia. Classic literature. <b>1994</b> , 165, 721-7		53
661	[Positive and negative symptoms in schizophrenia: a current overview]. <b>1994</b> , 39, 407-14		11
660	Work and meaning: disturbance of volition and vocational dysfunction in schizophrenia. <b>1995</b> , 58, 392-400		24
659	Sequential cross-sectional and 10-year prospective study of severe negative symptoms in relation to duration of initially untreated psychosis in chronic schizophrenia. <b>1995</b> , 25, 849-57		88
658	Positive and negative symptoms/syndromes in schizophrenia: reliability and validity of different diagnostic systems. <b>1995</b> , 25, 43-50		47
657	Negative symptoms and the course of positive symptoms in deficit schizophrenia. <b>1995</b> , 28, 121-6		
656	Primary enduring negative symptoms in schizophrenia and major depression. <b>1995</b> , 29, 297-302		17
655	Neuroleptic treatment and negative symptoms in deficit and nondeficit schizophrenia. <b>1995</b> , 38, 64-7		12
654	Drug development and the deficit syndrome of schizophrenia. <b>1995</b> , 38, 277-8		8
653	The reliability of distinguishing primary versus secondary negative symptoms. <b>1995</b> , 36, 421-7		37
652	The deficit syndrome in the DSM-IV Field Trial: I. Alcohol and other drug abuse. <i>Schizophrenia Research</i> , <b>1996</b> , 20, 69-77	3.6	103
651	The deficit syndrome in the DSM-IV Field Trial. Part II. Depressive episodes and persecutory beliefs. <i>Schizophrenia Research</i> , <b>1996</b> , 20, 79-90	3.6	53
650	The deficit syndrome in the Suffolk County Mental Health Project. <i>Schizophrenia Research</i> , <b>1996</b> , 22, 119-26	3.6	63
649	Family history and deficit form in schizophrenia. <b>1996</b> , 11, 260-2		20
648	Long-term studies of antipsychotic drugs in schizophrenia. <b>1996</b> , 11, 127-34		2
647	Adjunctive Antidepressant Drug Therapies in the Treatment of Negative Symptoms of Schizophrenia. <b>1996</b> , 6, 130-147		28

646	The Treatment of Negative Symptoms: Pharmacological and Methodological Issues. <b>1996</b> , 168, 17-22		21
645	Identifying subtypes of schizophrenia by cluster analyses. <i>Schizophrenia Bulletin</i> , <b>1996</b> , 22, 545-55	1.3	61
644	Attentional impairments in deficit and nondeficit forms of schizophrenia. <i>American Journal of Psychiatry</i> , <b>1997</b> , 154, 363-70	11.9	127
643	Clinical heterogeneity of schizophrenia. <b>1997</b> , 30, 275-81		4
642	Visual information-processing impairments in deficit and nondeficit schizophrenia. <i>American Journal of Psychiatry</i> , <b>1997</b> , 154, 647-54	11.9	69
641	The use of videotaped assessment in relation to a study of enhanced management in treatment-resistant schizophrenia. <b>1997</b> , 11, 357-60		3
640	The history of the psychopharmacology of schizophrenia. <b>1997</b> , 42, 152-62		62
639	Long-term outcome studies of schizophrenia: do females continue to display better outcome as expected?. <b>1997</b> , 9, 409-418		12
638	Borna disease virus antibodies and the deficit syndrome of schizophrenia. <i>Schizophrenia Research</i> , <b>1997</b> , 23, 253-7	3.6	68
637	Patients with deficit, nondeficit, and negative symptom schizophrenia: do they differ during episodes of acute psychotic decompensation?. <i>Schizophrenia Research</i> , <b>1997</b> , 24, 341-8	3.6	9
636	Glutamate in schizophrenia: clinical and research implications. <i>Schizophrenia Research</i> , <b>1997</b> , 27, 157-68	3.6	82
635	The deficit syndrome in first-admission patients with psychotic and non-psychotic disorders. <b>1997</b> , 12, 53-7		10
634	Eye tracking disorder in schizophrenia is characterized by specific ocular motor defects and is associated with the deficit syndrome. <b>1997</b> , 42, 781-96		54
633	Construct validity of negative symptoms: an empirical and conceptual review. <b>1997</b> , 17, 167-89		46
632	Affiliation and neuropsychiatric disorders: the deficit syndrome of schizophrenia. <b>1997</b> , 807, 455-68		27
631	Effects of the D3 and autoreceptor-preferring dopamine antagonist (+)-UH232 in schizophrenia. <b>1998</b> , 105, 719-34		33
630	Affect recognition in deficit syndrome schizophrenia. <i>Psychiatry Research</i> , <b>1998</b> , 77, 113-20	9.9	45
629	Prediction of the deficit syndrome from initial deficit symptoms in the early course of schizophrenia. <i>Psychiatry Research</i> , <b>1998</b> , 80, 53-9	9.9	22

628	Plasma 3-methoxy-4-hydroxyphenylglycol and homovanillic acid measurements in deficit and nondeficit forms of schizophrenia. <b>1998</b> , 43, 24-30		36
627	Antipsychotic properties of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine(preclamol) in schizophrenia. <b>1998</b> , 43, 2-11		92
626	D-serine added to antipsychotics for the treatment of schizophrenia. <b>1998</b> , 44, 1081-9		539
625	The structure of schizophrenic symptoms: a meta-analytic confirmatory factor analysis. <i>Schizophrenia Research</i> , <b>1998</b> , 31, 57-70	3.6	60
624	Recruitment of non-patient volunteers with schizophrenia spectrum personality symptoms. <i>Schizophrenia Research</i> , <b>1998</b> , 34, 181-6	3.6	12
623	Family history and obstetric complications in deficit and non-deficit schizophrenia: preliminary results. <b>1998</b> , 13, 270-2		15
622	Summer birth and the deficit syndrome of schizophrenia. <i>American Journal of Psychiatry</i> , <b>1998</b> , 155, 1221-6	6.9	60
621	Symptom structure in schizophrenia: two-, three- or four-factor models?. <b>1998</b> , 31, 120-30		41
620	Smooth pursuit eye movements to extraretinal motion signals: deficits in relatives of patients with schizophrenia. <b>1998</b> , 55, 830-6		86
619	Functional imaging of memory retrieval in deficit vs nondeficit schizophrenia. <b>1999</b> , 56, 1117-23		148
618	Atypical antipsychotics in older adults. <b>1999</b> , 19, 811-22		24
617	Interstitial cells of the white matter in the inferior parietal cortex in schizophrenia: An unbiased cell-counting study. <b>1999</b> , 34, 95-102		85
616	Atypical neuroleptics: a new approach in the treatment of negative symptoms. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , <b>1999</b> , 249 Suppl 4, 99-107	5.1	36
615	Deficit syndromes in schizophrenic patients 15 years after their first hospitalisation: preliminary results of a follow-up study. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , <b>1999</b> , 249 Suppl 4, 27-36	5.1	24
614	Therapeutic Synergism: Optimal Pharmacotherapy and Psychiatric Rehabilitation to Enhance Functional Outcome in Schizophrenia. <b>1999</b> , 3, 124-147		4
613	Emotional responding in deficit and non-deficit schizophrenia. <i>Psychiatry Research</i> , <b>1999</b> , 88, 191-207	9.9	94
612	Genetic antecedents of dopamine dysfunction in schizophrenia. <b>1999</b> , 45, 1143-50		14
611	Deficit psychopathology and a paradigm shift in schizophrenia research. <b>1999</b> , 46, 352-60		53

610	Enduring negative symptoms in first-episode psychosis: comparison of six methods using follow-up data. <i>Schizophrenia Research</i> , <b>1999</b> , 40, 147-58	3.6	86
609	Month of birth in deficit and non-deficit schizophrenic patients. <b>1999</b> , 14, 349-51		13
608	Apolipoprotein E-varepsilon4 frequency in deficit schizophrenia. <b>1999</b> , 14, 148-51		8
607	Anhedonia in the deficit syndrome of schizophrenia. <b>1999</b> , 32, 207-19		20
606	Will the novel antipsychotics significantly ameliorate neuropsychological deficits and improve adaptive functioning in schizophrenia?. <b>1999</b> , 29, 1-8		24
605	A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. <b>1999</b> , 56, 21-7		349
604	Sibling correlation of deficit syndrome in the Irish study of high-density schizophrenia families. <i>American Journal of Psychiatry</i> , <b>2000</b> , 157, 1071-6	11.9	49
603	Objective and subjective extrapyramidal side effects in schizophrenia: their relationships with negative and depressive symptoms. <b>2000</b> , 33, 125-30		16
602	Neurological signs and the heterogeneity of schizophrenia. <i>American Journal of Psychiatry</i> , <b>2000</b> , 157, 560-5	11.9	89
601	Differential efficacy of olanzapine for deficit and nondeficit negative symptoms in schizophrenia. <i>American Journal of Psychiatry</i> , <b>2000</b> , 157, 987-93	11.9	66
600	Risk factors for the deficit syndrome of schizophrenia. <i>Schizophrenia Bulletin</i> , <b>2000</b> , 26, 233-42	1.3	81
599	At Issue: Commentary on "A Default Analysis for Schizophrenia Research". <i>Schizophrenia Bulletin</i> , <b>2000</b> , 26, 163-165	1.3	3
598	Mazindol treatment of negative symptoms. <b>2000</b> , 23, 365-74		11
597	Assessing the efficacy of treatments for the deficit syndrome of schizophrenia. <b>2000</b> , 22, 303-10		40
596	Atypical antipsychotics: are some more atypical than others?. <b>2000</b> , 148, 3-15		126
595	[New i.e. atypical neuroleptic agents for negative symptoms of schizophrenia: results and methodological problems of evaluation]. <b>2000</b> , 71, 345-53		12
594	Psychopathology and wisconsin card sorting test performance in young unmedicated schizophrenic patients. <b>2000</b> , 33, 14-8		14
593	Proton magnetic resonance spectroscopy of the medial prefrontal cortex in patients with deficit schizophrenia: preliminary report. <i>American Journal of Psychiatry</i> , <b>2000</b> , 157, 641-3	11.9	47

592	Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. <i>American Journal of Psychiatry</i> , <b>2000</b> , 157, 549-59	11.9	733
591	At issue: a default analysis for schizophrenia research. <i>Schizophrenia Bulletin</i> , <b>2000</b> , 26, 157-61; discussion 163-5	1.3	3
590	Fine volumetric analysis of the cerebral ventricular system in schizophrenia: further evidence for multifocal mild to moderate enlargement. <i>Schizophrenia Bulletin</i> , <b>2000</b> , 26, 201-16	1.3	21
589	The deficit syndrome and eye tracking disorder may reflect a distinct subtype within the syndrome of schizophrenia. <i>Schizophrenia Bulletin</i> , <b>2000</b> , 26, 855-66	1.3	15
588	Relation of familial schizophrenia to negative symptoms but not to the deficit syndrome. <i>American Journal of Psychiatry</i> , <b>2000</b> , 157, 994-1003	11.9	71
587	MMPI discriminators of deficit vs. non-deficit recent-onset schizophrenia patients. <i>Psychiatry Research</i> , <b>2000</b> , 93, 111-23	9.9	24
586	A prospective longitudinal 10-year study of schizophrenia's three major factors and depression. <i>Psychiatry Research</i> , <b>2000</b> , 97, 61-77	9.9	64
585	Clozapine and negative symptoms. An open study. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2000</b> , 24, 373-84	5.5	7
584	Family characteristics of deficit and nondeficit schizophrenia in the Roscommon Family Study. <i>Schizophrenia Research</i> , <b>2000</b> , 45, 57-64	3.6	62
583	Saccadic eye movement abnormalities in relatives of patients with schizophrenia. <i>Schizophrenia Research</i> , <b>2000</b> , 45, 235-44	3.6	58
582	A five-year followup study of deficit and nondeficit schizophrenia. <i>Schizophrenia Research</i> , <b>2001</b> , 49, 253-60	3.6	100
581	Saccadic and smooth-pursuit eye movements in deficit and non-deficit schizophrenia. <i>Schizophrenia Research</i> , <b>2001</b> , 48, 145-53	3.6	45
580	Male gender is associated with deficit schizophrenia: a meta-analysis. <i>Schizophrenia Research</i> , <b>2001</b> , 47, 141-7	3.6	85
579	A separate disease within the syndrome of schizophrenia. <b>2001</b> , 58, 165-71		455
578	Memory and executive function impairments in deficit syndrome schizophrenia. <i>Psychiatry Research</i> , <b>2001</b> , 102, 29-37	9.9	86
577	Concordance of deficit and non-deficit subtypes in siblings affected with schizophrenia. <i>Psychiatry Research</i> , <b>2001</b> , 102, 59-64	9.9	7
576	Effects of chronic haloperidol and clozapine treatments on frontal and caudate neurochemistry in schizophrenia. <b>2001</b> , 107, 135-49		43
575	Schizophrenia. <b>2001</b> , 85, 663-89		17

574	Summer birth and deficit schizophrenia in Nithsdale, Scotland. <b>2001</b> , 189, 613-7		17
573	Summer birth and deficit schizophrenia in the epidemiological catchment area study. <b>2001</b> , 189, 608-12		27
572	Abnormal patterns of regional cerebral blood flow in schizophrenia with primary negative symptoms during an effortful auditory recognition task. <i>American Journal of Psychiatry</i> , <b>2001</b> , 158, 1797-808	11.9	88
571	Effects of ketamine in normal and schizophrenic volunteers. <b>2001</b> , 25, 455-67		478
570	Prefrontal cortex, negative symptoms, and schizophrenia: an MRI study. <b>2001</b> , 108, 65-78		133
569	Psychopathology Today. <b>2001</b> , 1-27		
568	Subtyping schizophrenia according to outcome or severity: a search for homogeneous subgroups. <i>Schizophrenia Bulletin</i> , <b>2001</b> , 27, 115-38	1.3	34
567	Recovery from psychotic illness: a 15- and 25-year international follow-up study. <b>2001</b> , 178, 506-17		707
566	Clinical profile of an atypical antipsychotic: risperidone. <i>Schizophrenia Bulletin</i> , <b>2002</b> , 28, 43-61	1.3	44
565	Historical, psychopathological, neurological, and neuropsychological aspects of deficit schizophrenia: a multicenter study. <i>American Journal of Psychiatry</i> , <b>2002</b> , 159, 983-90	11.9	112
564	Object relations deficits in schizophrenia: a cross-cultural comparison between Brazil and the United States. <b>2002</b> , 190, 73-9		10
563	Summer birth and deficit schizophrenia: Cantabria, Spain. <b>2002</b> , 190, 526-32		14
562	Amisulpride: is there a treatment for negative symptoms in schizophrenia patients?. <i>Schizophrenia Bulletin</i> , <b>2002</b> , 28, 193-201	1.3	28
561	Neurophysiological markers of vulnerability to schizophrenia: Sensitivity and specificity of specific quantitative eye movement measures.. <b>2002</b> , 111, 259-267		18
560	The course of anhedonia during 10 years of schizophrenic illness.. <b>2002</b> , 111, 237-248		53
559	Summer birth and deficit schizophrenia in Dumfries and Galloway, southwestern Scotland. <i>American Journal of Psychiatry</i> , <b>2002</b> , 159, 1382-7	11.9	44
558	The Lifetime Dimensions of Psychosis Scale (LDPS): description and interrater reliability. <i>Schizophrenia Bulletin</i> , <b>2002</b> , 28, 683-95	1.3	36
557	Odor identification, eye tracking and deficit syndrome schizophrenia. <b>2002</b> , 51, 809-15		65



556	D-Cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia. <i>Schizophrenia Research</i> , <b>2002</b> , 56, 19-23	3.6	101
555	The Kraepelinian dichotomy: preliminary results of a 15-year follow-up study on functional psychoses: focus on negative symptoms. <i>Schizophrenia Research</i> , <b>2002</b> , 56, 87-94	3.6	63
554	Borna disease virus and psychiatric disorders. <i>Schizophrenia Research</i> , <b>2002</b> , 57, 303-5	3.6	8
553	Cognitive patterns in subtypes of schizophrenia. <b>2002</b> , 17, 155-62		73
552	Sinistrality in subtypes of schizophrenia. <b>2002</b> , 17, 272-7		16
551	Stereotaxy-based regional brain volumetry applied to segmented MRI: validation and results in deficit and nondeficit schizophrenia. <b>2002</b> , 17, 373-84		44
550	Regional cerebral blood flow in deficit/nondeficit types of schizophrenia according to SDS criteria. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2002</b> , 26, 481-5	5.5	33
549	SPECT imaging, clinical features, and cognition before and after low doses of amisulpride in schizophrenic patients with the deficit syndrome. <b>2002</b> , 115, 37-48		31
548	Rating scales in mental health. Martha Sajatovic and Luis Ramirez. Hudson, Ohio: Lexi-Comp, Inc., 2001. 397 p with index.. <b>2002</b> , 16, 49-50		
547	Correlations between negative symptoms and peripheral G protein levels in mononuclear leukocytes of deficit and nondeficit schizophrenics. Preliminary results. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , <b>2002</b> , 252, 214-8	5.1	7
546	Negative symptoms in first episode non-affective psychosis. <b>2002</b> , 105, 431-9		85
545	A Tc-99m HMPAO SPECT study of regional cerebral blood flow in drug-free schizophrenic patients with deficit and non-deficit syndrome. <b>2003</b> , 123, 199-205		44
544	Borna disease virus and deficit schizophrenia. <b>2003</b> , 15, 262-5		4
543	A model of smooth pursuit eye movement deficit associated with the schizophrenia phenotype. <b>2003</b> , 40, 277-84		37
542	Substance abuse and the heterogeneity of schizophrenia a population-based study. <i>Schizophrenia Research</i> , <b>2003</b> , 62, 293-4	3.6	11
541	Components of the smooth pursuit function in deficit and nondeficit schizophrenia. <i>Schizophrenia Research</i> , <b>2003</b> , 63, 39-48	3.6	46
540	Neurocognitive, social, and emotional dysfunction in deficit syndrome schizophrenia. <i>Schizophrenia Research</i> , <b>2003</b> , 65, 125-37	3.6	75
539	Frontal lobe N-acetylaspartate correlates with psychopathology in schizophrenia: a proton magnetic resonance spectroscopy study. <i>Schizophrenia Research</i> , <b>2003</b> , 64, 63-71	3.6	62

538	Behavioural dysregulation of decision-making in deficit but not nondeficit schizophrenia patients. <i>Psychiatry Research</i> , <b>2003</b> , 119, 293-306	9.9	22
537	A brief smell identification test discriminates between deficit and non-deficit schizophrenia. <i>Psychiatry Research</i> , <b>2003</b> , 120, 155-64	9.9	36
536	Interstitial cells of the white matter in the dorsolateral prefrontal cortex in deficit and nondeficit schizophrenia. <b>2003</b> , 191, 563-7		70
535	Selective serotonin reuptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia. <b>2003</b> , 18, 305-13		31
534	The onset and time course of response of negative symptoms to add-on fluvoxamine treatment. <b>2003</b> , 18, 87-92		14
533	Olfaction and social drive in schizophrenia. <b>2003</b> , 60, 578-84		82
532	Self-reported stress and the deficit syndrome of schizophrenia. <b>2003</b> , 66, 308-16		21
531	Safety of quetiapine during pregnancy. <i>American Journal of Psychiatry</i> , <b>2003</b> , 160, 588-9	11.9	23
530	Clozapine and tardive dyskinesia. <i>American Journal of Psychiatry</i> , <b>2003</b> , 160, 588	11.9	29
529	Subjective Experience of Emotion in Schizophrenia. <b>2003</b> , 329-348		
528	Selective serotonin reuptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia. <b>2003</b> , 18, 305-313		8
527	Folate, homocysteine, and negative symptoms in schizophrenia. <i>American Journal of Psychiatry</i> , <b>2004</b> , 161, 1705-8	11.9	105
526	Selective serotonin re-uptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia. <b>2004</b> , 5, 2053-8		49
525	Deficit versus negative syndrome in schizophrenia: prediction of attentional impairment. <i>Schizophrenia Bulletin</i> , <b>2004</b> , 30, 827-35	1.3	26
524	Neuregulin 1: genetic support for schizophrenia subtypes. <b>2004</b> , 9, 1061-3		72
523	No association between polymorphisms of methylenetetrahydrofolate reductase gene and schizophrenia in both Chinese and Scottish populations. <b>2004</b> , 9, 1063-5		26
522	Relationship between performance on the Stroop test and N-acetylaspartate in the medial prefrontal cortex in deficit and nondeficit schizophrenia: preliminary results. <b>2004</b> , 132, 87-9		19
521	Attentional facilitation of response is impaired for antisaccades but not for saccades in patients with schizophrenia: implications for cortical dysfunction. <b>2004</b> , 159, 47-54		13

520	Affective reactivity of speech and emotional experience in patients with schizophrenia. <i>Schizophrenia Research</i> , <b>2004</b> , 69, 7-14	3.6	48
519	The timing of negative symptom exacerbations in relationship to positive symptom exacerbations in the early course of schizophrenia. <i>Schizophrenia Research</i> , <b>2004</b> , 69, 333-42	3.6	22
518	Olfactory identification and WAIS-R performance in deficit and nondeficit schizophrenia. <i>Schizophrenia Research</i> , <b>2004</b> , 69, 55-65	3.6	43
517	Effects of D-cycloserine on negative symptoms in schizophrenia. <i>Schizophrenia Research</i> , <b>2004</b> , 71, 239-48	3.6	74
516	Quality of life in schizophrenics with and without the deficit syndrome. <b>2004</b> , 19, 172-4		12
515	The deficit syndrome in schizophrenia: implications for the treatment of negative symptoms. <b>2004</b> , 19, 21-6		60
514	Trail making and olfaction in schizophrenia: implications for processing speed. <b>2004</b> , 9, 344-9, 356		8
513	Estimation of antipsychotic effects on hospitalization risk in a naturalistic study with selection on unobservables. <b>2004</b> , 192, 119-28		15
512	Five latent factors underlying schizophrenia: analysis and relationship to illnesses in relatives. <i>Schizophrenia Bulletin</i> , <b>2004</b> , 30, 855-73	1.3	29
511	Summer birth and deficit schizophrenia: a pooled analysis from 6 countries. <b>2004</b> , 61, 985-9		79
510	Diminished emotionality and social functioning in schizophrenia. <b>2005</b> , 193, 796-802		38
509	The negative symptoms of schizophrenia: a cognitive perspective. <b>2005</b> , 50, 247-57		165
508	Working memory functioning in schizophrenia patients and their first-degree relatives: cognitive functioning shedding light on etiology. <b>2005</b> , 43, 930-42		97
507	Dihydropyrimidinase-related protein 2 (DRP-2) gene and association to deficit and nondeficit schizophrenia. <b>2005</b> , 136B, 8-11		39
506	A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients. <b>2005</b> , 179, 144-50		88
505	Response to unexpected target changes during sustained visual tracking in schizophrenic patients. <b>2005</b> , 165, 125-31		25
504	Spatial working memory as a cognitive endophenotype of schizophrenia: assessing risk for pathophysiological dysfunction. <i>Schizophrenia Bulletin</i> , <b>2006</b> , 32, 498-506	1.3	66
503	Early detection of first-episode psychosis: the effect on 1-year outcome. <i>Schizophrenia Bulletin</i> , <b>2006</b> , 32, 758-64	1.3	75

502	Effects of noncompetitive NMDA receptor blockade on anterior cingulate cerebral blood flow in volunteers with schizophrenia. <b>2005</b> , 30, 2275-82		83
501	Olanzapine treatment of residual positive and negative symptoms. <i>American Journal of Psychiatry</i> , <b>2005</b> , 162, 124-9	11.9	36
500	[Neurocognitive changes and negative symptoms in schizophrenia]. <b>2005</b> , 73, 333-42		7
499	Catechol-O-methyltransferase Val158Met polymorphism in schizophrenia: associations with cognitive and motor impairment. <b>2005</b> , 52, 83-9		46
498	The subjective quality of life in deficit and nondeficit schizophrenic patients. <b>2005</b> , 20, 346-8		8
497	Strange feelings: do amygdala abnormalities dysregulate the emotional brain in schizophrenia?. <b>2005</b> , 77, 283-98		194
496	Impairments of executive/attentional functions in schizophrenia with primary and secondary negative symptoms. <i>Psychiatry Research</i> , <b>2005</b> , 133, 45-55	9.9	36
495	Antidepressants as add-on treatment to antipsychotics for people with schizophrenia and pronounced negative symptoms: a systematic review of randomized trials. <i>Schizophrenia Research</i> , <b>2005</b> , 80, 85-97	3.6	60
494	Treatment of schizophrenia negative symptoms: future prospects. <i>Schizophrenia Bulletin</i> , <b>2006</b> , 32, 234-7.3		134
493	[Comparative evaluation of quality of life in patients with schizophrenia treated with conventional versus atypical neuroleptics: results of a transversal study]. <b>2006</b> , 32, 459-65		2
492	Social class and type of schizophrenia. <b>2006</b> , 21, 233-7		22
491	Anhedonia in schizophrenia: a review of assessment strategies. <i>Schizophrenia Bulletin</i> , <b>2006</b> , 32, 259-73	1.3	237
490	0425 RELATIONSHIP BETWEEN DUP AND DUI AND CLINICAL FEATURES IN FIRST EPISODE OF SCHIZOPHRENIA-SPECTRUM DISORDERS. <i>Schizophrenia Research</i> , <b>2006</b> , 86, S123-S124	3.6	
489	D-alanine added to antipsychotics for the treatment of schizophrenia. <b>2006</b> , 59, 230-4		147
488	Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia. <b>2006</b> , 60, 645-9		148
487	Pharmacological treatment of primary negative symptoms in schizophrenia: a systematic review. <i>Schizophrenia Research</i> , <b>2006</b> , 88, 5-25	3.6	156
486	The T393C polymorphism of the GNAS1 gene is associated with deficit schizophrenia in an Italian population sample. <b>2006</b> , 397, 159-63		33
485	Kraepelinian subtype and deficit syndrome in chronic schizophrenia. <i>Psychiatry Research</i> , <b>2006</b> , 144, 221-5.9		8

484	Abnormal neurological signs, visual contrast sensitivity, and the deficit syndrome of schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2006</b> , 30, 1225-30	5.5	20
483	Avaliaço neuropsicolgica dos circuitos prfrontais relacionados  tomada de deciso na esquizofrenia: uma reviso sistemtica da literatura. <b>2006</b> , 28, 330-341		3
482	Clase social y tipo de esquizofrenia. <i>European Psychiatry (Ed Espaola)</i> , <b>2006</b> , 13, 329-334		
481	The Impact of Olfaction on Human Social Functioning. 220-232		2
480	Randomized, double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning. <b>2006</b> , 26, 453-61		54
479	The schizophrenia paradigm: a hundred-year challenge. <b>2006</b> , 194, 639-43		13
478	Fluvoxamine as an adjunctive agent in schizophrenia. <b>2001</b> , 7, 283-304		36
477	Correlations between rCBF and symptoms in two independent cohorts of drug-free patients with schizophrenia. <b>2006</b> , 31, 221-30		113
476	Neurocognitive functioning in patients with first-episode schizophrenia : results of a prospective 5-year follow-up study. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , <b>2006</b> , 256, 442-51	5.1	86
475	Correlations between clinical symptoms, working memory functions and structural brain abnormalities in men with schizophrenia. <b>2006</b> , 147, 47-55		34
474	Efficacy of amisulpride in treating primary negative symptoms in first-episode psychosis: a pilot study. <b>2006</b> , 21, 511-7		4
473	Negative signs and symptoms secondary to antipsychotics: a double-blind, randomized trial of a single dose of placebo, haloperidol, and risperidone in healthy volunteers. <i>American Journal of Psychiatry</i> , <b>2006</b> , 163, 488-93	11.9	94
472	The NIMH-MATRICES consensus statement on negative symptoms. <i>Schizophrenia Bulletin</i> , <b>2006</b> , 32, 214-91.3		846
471	Subdomains within the negative symptoms of schizophrenia: commentary. <i>Schizophrenia Bulletin</i> , <b>2006</b> , 32, 246-9	1.3	73
470	Deficit schizophrenia: association with serum antibodies to cytomegalovirus. <i>Schizophrenia Bulletin</i> , <b>2006</b> , 32, 396-400	1.3	61
469	The factorial structure of the schedule for the deficit syndrome in schizophrenia. <i>Schizophrenia Bulletin</i> , <b>2006</b> , 32, 274-8	1.3	87
468	The structure of negative symptoms within schizophrenia: implications for assessment. <i>Schizophrenia Bulletin</i> , <b>2006</b> , 32, 238-45	1.3	457
467	Patterns of structural MRI abnormalities in deficit and nondeficit schizophrenia. <i>Schizophrenia Bulletin</i> , <b>2008</b> , 34, 393-401	1.3	73

466	Contradictions of emotion in schizophrenia. <b>2007</b> , 21, 351-390		30
465	Induced gamma activity and event-related coherence in schizophrenia. <b>2007</b> , 38, 96-104		34
464	Neuropsychology of the deficit syndrome: new data and meta-analysis of findings to date. <i>Schizophrenia Bulletin</i> , <b>2007</b> , 33, 1201-12	1.3	132
463	The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. <i>American Journal of Psychiatry</i> , <b>2007</b> , 164, 1593-602	11.9	329
462	Persistent negative symptoms in schizophrenia: an overview. <i>Schizophrenia Bulletin</i> , <b>2007</b> , 33, 1013-22	1.3	294
461	One-year effect of changing duration of untreated psychosis in a single catchment area. <b>2007</b> , 51, s128-32		11
460	Summer birth and deficit schizophrenia in Tunisia. <i>Psychiatry Research</i> , <b>2007</b> , 152, 273-5	9.9	5
459	Schizophrenic subtype, seasonality of birth and social class: a preliminary analysis. <b>2007</b> , 22, 123-8		18
458	Clinical evaluation of negative symptoms in schizophrenia. <b>2007</b> , 22, 380-6		66
457	Apathy syndrome after traumatic brain injury compared with deficits in schizophrenia. <b>2007</b> , 48, 217-22		18
456	Clinique du déficit dans la schizophrénie. <b>2007</b> , 33, 2-4		0
455	Le traitement des formes déficitaires de schizophrénie. <b>2007</b> , 33, 11-15		0
454	Double dissociation of N1 and P3 abnormalities in deficit and nondeficit schizophrenia. <i>Schizophrenia Research</i> , <b>2007</b> , 92, 252-61	3.6	50
453	Validity of a 'proxy' for the deficit syndrome derived from the Positive And Negative Syndrome Scale (PANSS). <i>Schizophrenia Research</i> , <b>2007</b> , 93, 169-77	3.6	29
452	Early course of schizophrenia in a representative Dutch incidence cohort. <i>Schizophrenia Research</i> , <b>2007</b> , 97, 79-87	3.6	30
451	[Adaptation and validation into Spanish of Schedule for the Deficit Syndrome]. <b>2007</b> , 129, 91-3		12
450	Schizophrenia: measurements of psychopathology. <b>2007</b> , 30, 339-63		22
449	Early Psychosis Prevention and Intervention Centre long-term follow-up study of first-episode psychosis: methodology and baseline characteristics. <b>2007</b> , 1, 49-60		34

448	The PIP5K2A and RGS4 genes are differentially associated with deficit and non-deficit schizophrenia. <b>2007</b> , 6, 113-9		58
447	Negative symptoms of schizophrenia: a problem that will not go away. <b>2007</b> , 115, 4-11		121
446	Schizophrenia: disease, syndrome, or dimensions?. <b>2007</b> , 46, 199-206		14
445	Potiation of the NMDA receptor in the treatment of schizophrenia: focused on the glycine site. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , <b>2008</b> , 258, 16-27	5.1	76
444	Clinical trials report. <b>2008</b> , 10, 137-139		
443	Recurrent CNVs disrupt three candidate genes in schizophrenia patients. <b>2008</b> , 83, 504-10		220
442	Neuropsychological impairment in deficit vs. non-deficit schizophrenia. <b>2008</b> , 42, 930-7		31
441	Patterns of cranial, brain and sulcal CSF volumes in male and female deficit and nondeficit patients with schizophrenia. <b>2008</b> , 162, 91-100		22
440	How to find the way out from four rooms? The learning of "chaining" associations may shed light on the neuropsychology of the deficit syndrome of schizophrenia. <i>Schizophrenia Research</i> , <b>2008</b> , 99, 200-7	3.6	33
439	Prevalence of 22q11.2 deletions in 311 Dutch patients with schizophrenia. <i>Schizophrenia Research</i> , <b>2008</b> , 98, 84-8	3.6	29
438	Schizoid-like features and season of birth in a nonpatient sample. <i>Schizophrenia Research</i> , <b>2008</b> , 103, 151-5	3.6	15
437	Emotion recognition in Chinese people with schizophrenia. <i>Psychiatry Research</i> , <b>2008</b> , 157, 67-76	9.9	22
436	Psychopathology and neuropsychological impairments in deficit and nondeficit schizophrenia of Chinese origin. <i>Psychiatry Research</i> , <b>2008</b> , 158, 195-205	9.9	49
435	Elevated nailfold plexus visibility aggregates in families and is associated with a specific negative symptom pattern in schizophrenia. <i>Psychiatry Research</i> , <b>2008</b> , 160, 30-7	9.9	6
434	Social class, family history and type of schizophrenia. <i>Psychiatry Research</i> , <b>2008</b> , 159, 127-32	9.9	12
433	A two-factor structure for the Schedule for the Deficit Syndrome in schizophrenia. <i>Psychiatry Research</i> , <b>2008</b> , 158, 256-9	9.9	44
432	Automatic affective processing impairments in patients with deficit syndrome schizophrenia. <i>Schizophrenia Research</i> , <b>2008</b> , 102, 76-87	3.6	42
431	Context, complexity, and cognitive processing in schizophrenia. <b>2008</b> , 13, 250-66		4

430	Negative symptoms in schizophrenia: a review. <b>2008</b> , 62, 334-41		102
429	Modafinil: A Candidate for Pharmacotherapy of Negative Symptoms in Schizophrenia. <b>2008</b> , 3,		
428	Prevention of negative symptom psychopathologies in first-episode schizophrenia: two-year effects of reducing the duration of untreated psychosis. <b>2008</b> , 65, 634-40		141
427	Deficit schizophrenia: an update. <b>2008</b> , 7, 143-7		135
426	Narrating emotional events in schizophrenia. <b>2008</b> , 117, 520-33		21
425	Associative learning in deficit and nondeficit schizophrenia. <b>2008</b> , 19, 55-8		29
424	The Neurobiology of Negative Symptoms and the Deficit Syndrome. <b>2009</b> , 505-523		
423	Familiarity of novel factorial dimensions of schizophrenia. <b>2009</b> , 66, 591-600		61
422	White matter alterations in deficit schizophrenia. <b>2009</b> , 34, 1514-22		114
421	Working memory and DLPFC inefficiency in schizophrenia: the FBIRN study. <i>Schizophrenia Bulletin</i> , <b>2009</b> , 35, 19-31	1.3	258
420	Association study of NRG1, DTNBP1, RGS4, G72/G30, and PIP5K2A with schizophrenia and symptom severity in a Hungarian sample. <b>2010</b> , 153B, 792-801		31
419	Anhedonia in schizophrenia and major depression: state or trait?. <b>2009</b> , 8, 22		127
418	[Validation of the Temporal Experience of Pleasure Scale (TEPS) in a French-speaking environment]. <b>2009</b> , 35, 241-8		55
417	In support of Bleuler: objective evidence for increased affective ambivalence in schizophrenia based upon evocative testing. <i>Schizophrenia Research</i> , <b>2009</b> , 107, 223-31	3.6	64
416	Differences in glucose tolerance between deficit and nondeficit schizophrenia. <i>Schizophrenia Research</i> , <b>2009</b> , 107, 122-7	3.6	53
415	Characterization of affective domains within the nonaffective psychotic disorders. <i>Schizophrenia Research</i> , <b>2009</b> , 111, 61-9	3.6	20
414	Insights from the examination of verbal and spatial memory errors in relation to clinical symptoms of patients with recent-onset schizophrenia. <b>2009</b> , 14, 542-58		2
413	Deficit schizophrenia: an overview of clinical, biological and treatment aspects. <b>2009</b> , 24, 493-500		66



412 [Psychopathologic and cognitive investigations in schizophrenia]. **2009**, 150, 423-9

411 Two subgroups of schizophrenia identified by systematic cognitive neuropsychiatric mapping. *European Archives of Psychiatry and Clinical Neuroscience*, **2010**, 260, 257-66 5.1 17

410 The Munich 15-year follow-up study (MUFUSSAD) on first-hospitalized patients with schizophrenic or affective disorders: comparison of psychopathological and psychosocial course and outcome and prediction of chronicity. *European Archives of Psychiatry and Clinical Neuroscience*, **2010**, 260, 367-84 5.1 46

409 Assessment of pharmacotherapy for negative symptoms of schizophrenia. **2010**, 12, 563-71 37

408 Olfactory hedonic judgment in patients with deficit syndrome schizophrenia. *Schizophrenia Bulletin*, **2010**, 36, 860-8 1.3 53

407 Negative symptoms in schizophrenia: avolition and Occam's razor. *Schizophrenia Bulletin*, **2010**, 36, 359-69 3 419

406 Periods of recovery in deficit syndrome schizophrenia: a 20-year multi-follow-up longitudinal study. *Schizophrenia Bulletin*, **2010**, 36, 788-99 1.3 136

405 Impaired smooth pursuit in schizophrenia results from prediction impairment only. **2010**, 67, 992-7 19

404 The psychiatric symptomatology of deficit schizophrenia: a meta-analysis. *Schizophrenia Research*, **2010**, 118, 122-7 3.6 41

403 Apathy in first episode psychosis patients: one year follow up. *Schizophrenia Research*, **2010**, 116, 20-6 3.6 59

402 Deficit schizophrenia does not co-aggregate with high nailfold plexus visibility. *Schizophrenia Research*, **2010**, 123, 88-9 3.6 1

401 Impaired decision making in schizophrenia and orbitofrontal cortex lesion patients. *Schizophrenia Research*, **2010**, 116, 266-73 3.6 44

400 P50 gating in deficit and nondeficit schizophrenia. *Schizophrenia Research*, **2010**, 119, 183-90 3.6 30

399 Impaired facial affect labeling and discrimination in patients with deficit syndrome schizophrenia. *Schizophrenia Research*, **2010**, 118, 146-53 3.6 41

398 Gray-matter abnormalities in deficit schizophrenia. *Schizophrenia Research*, **2010**, 120, 63-70 3.6 66

397 Executive function in deficit schizophrenia: what do the dimensions of the Wisconsin Card Sorting Test tell us?. *Schizophrenia Research*, **2010**, 122, 85-93 3.6 44

396 Clinical significance of neurological soft signs in schizophrenia: factor analysis of the Neurological Evaluation Scale. *Schizophrenia Research*, **2010**, 124, 1-12 3.6 26

395 Initial development and preliminary validation of a new negative symptom measure: the Clinical Assessment Interview for Negative Symptoms (CAINS). *Schizophrenia Research*, **2010**, 124, 36-42 3.6 72

394	Progress in defining optimal treatment outcome in schizophrenia. <b>2010</b> , 24, 9-20		51
393	Nonresponse to clozapine and premorbid functioning in treatment of refractory schizophrenia. <b>2010</b> , 51, 298-302		10
392	Negative symptoms and their predictors in schizophrenia within the Northern Finland 1966 Birth Cohort. <i>Psychiatry Research</i> , <b>2010</b> , 178, 121-5	9.9	21
391	A framework for understanding experiential deficits in schizophrenia. <i>Psychiatry Research</i> , <b>2010</b> , 178, 10-6	9.9	17
390	Escitalopram in the treatment of negative symptoms in patients with chronic schizophrenia: a randomized double-blind placebo-controlled trial. <i>Psychiatry Research</i> , <b>2010</b> , 179, 19-23	9.9	22
389	Stimulation magnétique transcrânienne répétée (rTMS) et symptômes négatifs de la schizophrénie. <b>2010</b> , 168, 422-427		5
388	Impaired insight in patients with newly diagnosed nonaffective psychotic disorders with and without deficit features. <i>Schizophrenia Research</i> , <b>2011</b> , 126, 252-6	3.6	18
387	Deficit and nondeficit schizophrenia: boundaries in question. <i>Schizophrenia Research</i> , <b>2011</b> , 130, 289-90	3.6	5
386	Insight controlled for cognition in deficit and nondeficit schizophrenia. <i>Schizophrenia Research</i> , <b>2011</b> , 128, 124-6	3.6	15
385	Paternal age related schizophrenia (PARS): Latent subgroups detected by k-means clustering analysis. <i>Schizophrenia Research</i> , <b>2011</b> , 128, 143-9	3.6	41
384	Neuromotor abnormalities in neuroleptic-naive psychotic patients: antecedents, clinical correlates, and prediction of treatment response. <b>2011</b> , 52, 139-45		45
383	Avolition and expressive deficits capture negative symptom phenomenology: implications for DSM-5 and schizophrenia research. <b>2011</b> , 31, 161-8		191
382	A cognitive regulatory control model of schizophrenia. <b>2011</b> , 85, 36-41		6
381	The brief negative symptom scale: psychometric properties. <i>Schizophrenia Bulletin</i> , <b>2011</b> , 37, 300-5	1.3	454
380	Persistent negative symptoms in first-episode schizophrenia: a prospective three-year follow-up study. <i>Schizophrenia Research</i> , <b>2011</b> , 133, 22-8	3.6	93
379	Psychopathology, coronary heart disease and metabolic syndrome in schizophrenia spectrum patients with deficit versus non-deficit schizophrenia: findings from the CLAMORS study. <b>2011</b> , 21, 867-75		24
378	Tardive dyskinesia and deficit schizophrenia. <b>2011</b> , 124, 357-62		20
377	The negative symptoms of schizophrenia: category or continuum?. <b>2011</b> , 44, 345-53		53

376	Understanding constricted affect in schizotypy through computerized prosodic analysis. <b>2011</b> , 25, 478-91		22
375	Toward the next generation of negative symptom assessments: the collaboration to advance negative symptom assessment in schizophrenia. <i>Schizophrenia Bulletin</i> , <b>2011</b> , 37, 291-9	1.3	189
374	Posttraumatic stress disorder and negative symptoms of schizophrenia. <i>Schizophrenia Bulletin</i> , <b>2011</b> , 37, 603-10	1.3	18
373	Social anhedonia and schizotypy in a community sample: the Maryland longitudinal study of schizotypy. <i>Schizophrenia Bulletin</i> , <b>2011</b> , 37, 587-602	1.3	118
372	Neurocognition and neuroimaging of persistent negative symptoms of schizophrenia. <i>Expert Review of Neurotherapeutics</i> , <b>2012</b> , 12, 53-69	4.3	54
371	Striatal function in relation to negative symptoms in schizophrenia. <b>2012</b> , 42, 267-82		31
370	Neurological soft signs as an endophenotype in siblings of deficit versus nondeficit schizophrenic patients. <b>2012</b> , 19, 85-97		1
369	Cognitive insight and its relationship with symptoms in deficit and nondeficit schizophrenia. <b>2012</b> , 200, 44-50		5
368	Next-generation negative symptom assessment for clinical trials: validation of the Brief Negative Symptom Scale. <i>Schizophrenia Research</i> , <b>2012</b> , 142, 88-92	3.6	125
367	Factor structure of the Brief Negative Symptom Scale. <i>Schizophrenia Research</i> , <b>2012</b> , 142, 96-8	3.6	135
366	Inflammatory markers in antipsychotic-naïve patients with nonaffective psychosis and deficit vs. nondeficit features. <i>Psychiatry Research</i> , <b>2012</b> , 198, 212-5	9.9	61
365	Does the Internet offer social opportunities for individuals with schizophrenia? A cross-sectional pilot study. <i>Psychiatry Research</i> , <b>2012</b> , 198, 319-20	9.9	24
364	Dorsolateral prefrontal cortex volume in patients with deficit or nondeficit schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2012</b> , 37, 264-9	5.5	29
363	People living with psychotic illness in 2010: the second Australian national survey of psychosis. <i>Australian and New Zealand Journal of Psychiatry</i> , <b>2012</b> , 46, 735-52	2.6	347
362	Differential patterns of premorbid social and academic deterioration in deficit and nondeficit schizophrenia. <i>Schizophrenia Research</i> , <b>2012</b> , 135, 134-8	3.6	47
361	Olfactory processing, sex effects and heterogeneity in schizophrenia. <i>Schizophrenia Research</i> , <b>2012</b> , 135, 144-51	3.6	29
360	Screening for negative symptoms: preliminary results from the self-report version of the Clinical Assessment Interview for Negative Symptoms. <i>Schizophrenia Research</i> , <b>2012</b> , 135, 139-43	3.6	30
359	Cortical structural abnormalities in deficit versus nondeficit schizophrenia. <i>Schizophrenia Research</i> , <b>2012</b> , 136, 51-4	3.6	44

358	Behavioral validation of avolition in schizophrenia. <i>Schizophrenia Research</i> , <b>2012</b> , 138, 255-61	3.6	19
357	Flat affect and social functioning: a 10 year follow-up study of first episode psychosis patients. <i>Schizophrenia Research</i> , <b>2012</b> , 139, 99-104	3.6	38
356	Identifying persistent negative symptoms in first episode psychosis. <b>2012</b> , 12, 224		55
355	The structural neural substrates of persistent negative symptoms in first-episode of non-affective psychosis: a voxel-based morphometry study. <i>Frontiers in Psychiatry</i> , <b>2012</b> , 3, 42	5	28
354	Depression and schizophrenia. <b>2012</b> , 18, 280-288		7
353	Genetic Risk and Outcome of Psychosis (GROUP), a multi-site longitudinal cohort study focused on gene-environment interaction: objectives, sample characteristics, recruitment and assessment methods. <b>2012</b> , 21, 205-21		179
352	Reduced left uncinate fasciculus fractional anisotropy in deficit schizophrenia but not in non-deficit schizophrenia. <b>2012</b> , 66, 34-43		56
351	Detection of metabolites in the white matter of frontal lobes and hippocampus with proton in first-episode treatment-naïve schizophrenia patients. <b>2012</b> , 6, 166-75		10
350	General and domain-specific neurocognitive impairments in deficit and non-deficit schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , <b>2012</b> , 262, 107-15	5.1	31
349	The effects of physical exercise in schizophrenia and affective disorders. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , <b>2013</b> , 263, 451-67	5.1	61
348	BDNF rs 6265 polymorphism and COMT rs 4680 polymorphism in deficit schizophrenia in Polish sample. <b>2013</b> , 65, 1185-93		24
347	Deconstructing negative symptoms of schizophrenia: avolition-apathy and diminished expression clusters predict clinical presentation and functional outcome. <b>2013</b> , 47, 783-90		269
346	Genome-wide linkage scan of quantitative traits representing symptom dimensions in multiplex schizophrenia families. <i>Psychiatry Research</i> , <b>2013</b> , 210, 756-60	9.9	10
345	Using negative feedback to guide behavior: impairments on the first 4 cards of the Wisconsin Card Sorting Test predict negative symptoms of schizophrenia. <i>Schizophrenia Research</i> , <b>2013</b> , 151, 97-101	3.6	11
344	Persistent negative symptoms in first episode patients with schizophrenia: results from the European First Episode Schizophrenia Trial. <b>2013</b> , 23, 196-204		99
343	Computerized facial analysis for understanding constricted/blunted affect: initial feasibility, reliability, and validity data. <i>Schizophrenia Research</i> , <b>2013</b> , 148, 111-6	3.6	28
342	A new Integrated Negative Symptom structure of the Positive and Negative Syndrome Scale (PANSS) in schizophrenia using item response analysis. <i>Schizophrenia Research</i> , <b>2013</b> , 150, 185-96	3.6	15
341	Prevalence of negative symptoms and associated factors in older adults with schizophrenia spectrum disorder. <b>2013</b> , 21, 100-7		9

340	Reduced anterior cingulate gray matter volume and thickness in subjects with deficit schizophrenia. <i>Schizophrenia Research</i> , <b>2013</b> , 150, 484-90	3.6	34
339	Two subdomains of negative symptoms in psychotic disorders: established and confirmed in two large cohorts. <b>2013</b> , 47, 718-25		135
338	Reduced total antioxidant level and increased oxidative stress in patients with deficit schizophrenia: a preliminary study. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2013</b> , 45, 144-9	5.5	28
337	Orbitofrontal cortex abnormality and deficit schizophrenia. <i>Schizophrenia Research</i> , <b>2013</b> , 143, 246-52	3.6	57
336	Correlation between insight dimensions and cognitive functions in patients with deficit and nondeficit schizophrenia. <i>Schizophrenia Research</i> , <b>2013</b> , 147, 91-94	3.6	20
335	Dysfunctional attitudes and expectancies in deficit syndrome schizophrenia. <i>Schizophrenia Bulletin</i> , <b>2013</b> , 39, 43-51	1.3	64
334	Distinct episodic verbal memory profiles in schizophrenia. <b>2013</b> , 3, 192-205		5
333	Increased stress reactivity: a mechanism specifically associated with the positive symptoms of psychotic disorder. <b>2013</b> , 43, 1389-400		58
332	Secondary nonmotor negative symptoms in healthy volunteers after single doses of haloperidol and risperidone: a double-blind, crossover, placebo-controlled trial. <b>2013</b> , 28, 586-93		14
331	Hippocampal volume reduction correlates with apathy in traumatic brain injury, but not schizophrenia. <b>2013</b> , 25, 292-301		18
330	Multi-components of evoked-brain potentials in deficit and nondeficit schizophrenia. <b>2013</b> , 5, 69-79		13
329	Cognition as a central illness feature in schizophrenia. 1-23		4
328	Comparative impairments across schizophrenia and bipolar disorder. 50-68		1
327	Correlation of Lifetime Symptom Dimensions with Cognitive Function and Other Clinical Characteristics in Schizophrenia Patients. <b>2014</b> , 17, 72		
326	Cortical thinning in temporo-parietal junction (TPJ) in non-affective first-episode of psychosis patients with persistent negative symptoms. <b>2014</b> , 9, e101372		30
325	Genes and schizophrenia: from a Festschrift Seminar honoring William T. Carpenter Jr, MD. <i>Schizophrenia Bulletin</i> , <b>2014</b> , 40 Suppl 2, S117-22	1.3	1
324	Negative symptoms in schizophrenia. <b>2014</b> , 8, 28-35B		14
323	Characterization of the deficit syndrome in drug-naive schizophrenia patients: the role of spontaneous movement disorders and neurological soft signs. <i>Schizophrenia Bulletin</i> , <b>2014</b> , 40, 214-24	1.3	59

322	Electrophysiology and Psychophysiology in Psychiatry and Psychopharmacology. <b>2014</b> ,		1
321	Plasma cortisol levels and illness appraisal in deficit syndrome schizophrenia. <i>Psychiatry Research</i> , <b>2014</b> , 220, 765-71	9.9	10
320	Executive functioning and psychopathological profile in relatives of individuals with deficit v. non-deficit schizophrenia: a pilot study. <b>2014</b> , 23, 85-97		6
319	Attenuation of anhedonia by cariprazine in the chronic mild stress model of depression. <b>2014</b> , 25, 567-74		56
318	Neurocognitive functioning of individuals with schizophrenia: using and not using drugs. <i>Schizophrenia Bulletin</i> , <b>2014</b> , 40, 856-67	1.3	25
317	A sex-specified effect of obstetrical complications in symptoms of schizophrenia. <b>2014</b> , 8, 143-148A		2
316	The risk of diabetes in deficit schizophrenia. <b>2014</b> , 7, 235-7		
315	Defining and measuring negative symptoms of schizophrenia in clinical trials. <b>2014</b> , 24, 737-43		48
314	Revisiting the therapeutic effect of rTMS on negative symptoms in schizophrenia: a meta-analysis. <i>Psychiatry Research</i> , <b>2014</b> , 215, 505-13	9.9	91
313	Negative symptoms of schizophrenia: clinical features, relevance to real world functioning and specificity versus other CNS disorders. <b>2014</b> , 24, 693-709		124
312	Progress in the study of negative symptoms. <i>Schizophrenia Bulletin</i> , <b>2014</b> , 40 Suppl 2, S101-6	1.3	24
311	Assessment of trait and state aspects of depression in schizophrenia. <i>Schizophrenia Bulletin</i> , <b>2014</b> , 40, 132-42	1.3	33
310	Schizophrenia miR-137 locus risk genotype is associated with dorsolateral prefrontal cortex hyperactivation. <b>2014</b> , 75, 398-405		59
309	Negative symptoms, past and present: a historical perspective and moving to DSM-5. <b>2014</b> , 24, 710-24		33
308	What do we really know about blunted vocal affect and alogia? A meta-analysis of objective assessments. <i>Schizophrenia Research</i> , <b>2014</b> , 159, 533-8	3.6	45
307	Impaired processing speed and attention in first-episode drug naive schizophrenia with deficit syndrome. <i>Schizophrenia Research</i> , <b>2014</b> , 159, 478-84	3.6	26
306	Low vitamin D levels predict clinical features of schizophrenia. <i>Schizophrenia Research</i> , <b>2014</b> , 159, 543-5	3.6	41
305	Electrophysiological aberrations associated with negative symptoms in schizophrenia. <b>2014</b> , 21, 129-56		26

304	A review of reward processing and motivational impairment in schizophrenia. <i>Schizophrenia Bulletin</i> , <b>2014</b> , 40 Suppl 2, S107-16	1.3	256
303	First-episode psychosis and migration in Italy (PEP-Ita migration): a study in the Italian mental health services. <b>2014</b> , 14, 186		9
302	Impact of primary negative symptoms on functional outcomes in schizophrenia. <b>2014</b> , 29, 449-55		120
301	Theory of mind impairments in patients with deficit schizophrenia. <b>2014</b> , 55, 349-56		19
300	Motivational Deficits in Schizophrenia and the Representation of Expected Value. <b>2016</b> , 27, 375-410		44
299	Baseline social amotivation predicts 1-year functioning in UHR subjects: A validation and prospective investigation. <b>2015</b> , 25, 2187-96		14
298	White matter alterations in first episode treatment-naïve patients with deficit schizophrenia: a combined VBM and DTI study. <b>2015</b> , 5, 12994		33
297	Decreased serum levels of brain-derived neurotrophic factor in schizophrenic patients with deficit syndrome. <b>2015</b> , 11, 865-72		9
296	Neurological soft signs might be endophenotype candidates for patients with deficit syndrome schizophrenia. <b>2015</b> , 11, 2825-31		9
295	Gender Differences in the Physical and Psychological Manifestation of Childhood Trauma and/or Adversity in People with Psychosis. <b>2015</b> , 6, 1768		25
294	Association Between Serum Anticholinergic Activity and Psychiatric Symptoms of Chronic Schizophrenia. <b>2015</b> , 27, 251-260		
293	Olfactory performance segregates effects of anhedonia and anxiety on social function in patients with schizophrenia. <i>Journal of Psychiatry and Neuroscience</i> , <b>2015</b> , 40, 387-93	4.5	13
292	Is avolition in schizophrenia associated with a deficit of dorsal caudate activity? A functional magnetic resonance imaging study during reward anticipation and feedback. <b>2015</b> , 45, 1765-78		84
291	Dopamine supersensitivity psychosis as a pivotal factor in treatment-resistant schizophrenia. <i>Psychiatry Research</i> , <b>2015</b> , 227, 278-82	9.9	58
290	[Psychopathological aspects of negative symptoms in schizophrenia]. <b>2015</b> , 41, 6S9-14		
289	[Use of antidepressants in the treatment of negative symptoms of schizophrenia]. <b>2015</b> , 41, 6S36-40		1
288	Dissecting negative symptoms in schizophrenia: opportunities for translation into new treatments. <b>2015</b> , 29, 116-26		36
287	Functional polymorphism of matrix metalloproteinase-9 (MMP9) gene is not associated with schizophrenia and with its deficit subtype. <b>2015</b> , 67, 442-5		11



286	Predictors of neuropsychological effort test performance in schizophrenia. <i>Schizophrenia Research</i> , <b>2015</b> , 162, 205-10	3.6	16
285	Concepts and methods when considering negative symptom course. <b>2015</b> , 45, 2135-6		6
284	Contingent negative variation in patients with deficit schizophrenia or bipolar I disorder with psychotic features: measurement and correlation with clinical characteristics. <b>2015</b> , 69, 196-203		14
283	Brain structure abnormalities in first-episode psychosis patients with persistent apathy. <i>Schizophrenia Research</i> , <b>2015</b> , 164, 59-64	3.6	32
282	Quantifying motivational deficits and apathy: a review of the literature. <b>2015</b> , 25, 1060-81		17
281	Brain white matter microstructure in deficit and non-deficit subtypes of schizophrenia. <b>2015</b> , 231, 252-61		25
280	Further neuroimaging evidence for the deficit subtype of schizophrenia: a cortical connectomics analysis. <b>2015</b> , 72, 446-55		56
279	The Brief Negative Symptom Scale (BNSS): Independent validation in a large sample of Italian patients with schizophrenia. <b>2015</b> , 30, 641-7		71
278	Gray matter volume alterations in first-episode drug-naïve patients with deficit and nondeficit schizophrenia. <b>2015</b> , 234, 219-226		14
277	Negative symptom domain prevalence across diagnostic boundaries: The relevance of diagnostic shifts. <i>Psychiatry Research</i> , <b>2015</b> , 228, 347-54	9.9	16
276	Are Negative Symptoms Dimensional or Categorical? Detection and Validation of Deficit Schizophrenia With Taxometric and Latent Variable Mixture Models. <i>Schizophrenia Bulletin</i> , <b>2015</b> , 41, 879-91	1.3	55
275	A comparison of schizophrenia, schizoaffective disorder, and bipolar disorder: Results from the Second Australian national psychosis survey. <b>2015</b> , 172, 30-7		34
274	Motor abnormalities and basal ganglia in schizophrenia: evidence from structural magnetic resonance imaging. <b>2015</b> , 28, 135-52		23
273	Validation of the Korean-Version of the Clinical Assessment Interview for Negative Symptoms of Schizophrenia (CAINS). <b>2016</b> , 31, 1114-20		13
272	Confirmatory Factor Analysis and Differential Relationships of the Two Subdomains of Negative Symptoms in Chronically Ill Psychotic Patients. <b>2016</b> , 11, e0149785		24
271	Increased serum levels of apoptosis in deficit syndrome schizophrenia patients: a preliminary study. <b>2016</b> , 12, 1261-8		7
270	Treatment resistant schizophrenia: Course of brain structure and function. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2016</b> , 70, 111-6	5.5	13
269	Odors identification differences in deficit and nondeficit schizophrenia. <b>2016</b> , 68, 390-5		7



268	Awareness of Pre-diabetes or Diabetes and Associated Factors in People With Psychosis. <i>Schizophrenia Bulletin</i> , <b>2016</b> , 42, 1280-9	1.3	8
267	Avolition, Negative Symptoms, and a Clinical Science Journey and Transition to the Future. <b>2016</b> , 63, 133-58		
266	Association of the brain-derived neurotrophic factor Val66Met polymorphism with negative symptoms severity, but not cognitive function, in first-episode schizophrenia spectrum disorders. <b>2016</b> , 38, 61-69		12
265	Facial emotion recognition and alexithymia in Chinese male patients with deficit schizophrenia. <i>Psychiatry Research</i> , <b>2016</b> , 246, 353-359	9.9	12
264	Validation of Turkish version of brief negative symptom scale. <b>2016</b> , 20, 265-71		17
263	Left nucleus accumbens atrophy in deficit schizophrenia: A preliminary study. <b>2016</b> , 254, 48-55		9
262	The Neuropsychopathology of Schizophrenia. <b>2016</b> ,		1
261	Premorbid, clinical and cognitive correlates of primary negative symptoms in first-episode psychosis. <i>Psychiatry Research</i> , <b>2016</b> , 242, 144-149	9.9	17
260	Risperidone (depot) for schizophrenia. <b>2016</b> , 4, CD004161		12
259	Familiarity of Psychotic Disorders: A Polynologic Study in Multiplex Families. <i>Schizophrenia Bulletin</i> , <b>2016</b> , 42, 975-83	1.3	19
258	Impact of dopamine supersensitivity psychosis in treatment-resistant schizophrenia: An analysis of multi-factors predicting long-term prognosis. <i>Schizophrenia Research</i> , <b>2016</b> , 170, 252-8	3.6	19
257	Self-Evaluation of Negative Symptoms: A Novel Tool to Assess Negative Symptoms. <i>Schizophrenia Bulletin</i> , <b>2016</b> , 42, 571-8	1.3	55
256	Reward anticipation and trait anhedonia: An electrophysiological investigation in subjects with schizophrenia. <b>2016</b> , 127, 2149-60		28
255	Characterization of premorbid functioning during childhood in patients with deficit vs. non-deficit schizophrenia and in their healthy siblings. <i>Schizophrenia Research</i> , <b>2016</b> , 174, 172-176	3.6	18
254	Disconnection Between Amygdala and Medial Prefrontal Cortex in Psychotic Disorders. <i>Schizophrenia Bulletin</i> , <b>2016</b> , 42, 1056-67	1.3	32
253	Prefrontal neuronal integrity predicts symptoms and cognition in schizophrenia and is sensitive to genetic heterogeneity. <i>Schizophrenia Research</i> , <b>2016</b> , 172, 94-100	3.6	8
252	[Scale for assessing negative symptoms in schizophrenia: A systematic review]. <b>2016</b> , 42, 165-71		7
251	The Function Biomedical Informatics Research Network Data Repository. <b>2016</b> , 124, 1074-1079		53

250	Neurocognitive impairment in the deficit subtype of schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , <b>2016</b> , 266, 397-407	5.1	18
249	Hypo-metabolism of the rostral anterior cingulate cortex associated with working memory impairment in 18 cases of schizophrenia. <b>2016</b> , 10, 115-23		9
248	Current developments and challenges in the assessment of negative symptoms. <i>Schizophrenia Research</i> , <b>2017</b> , 186, 8-18	3.6	54
247	Primary and persistent negative symptoms: Concepts, assessments and neurobiological bases. <i>Schizophrenia Research</i> , <b>2017</b> , 186, 19-28	3.6	72
246	Secondary negative symptoms - A review of mechanisms, assessment and treatment. <i>Schizophrenia Research</i> , <b>2017</b> , 186, 29-38	3.6	96
245	Dissecting negative symptoms of schizophrenia: History, assessment, pathophysiological mechanisms and treatment. <i>Schizophrenia Research</i> , <b>2017</b> , 186, 1-2	3.6	21
244	Influence of early trauma on features of schizophrenia. <b>2017</b> , 11, 322-333		41
243	Aberrant spontaneous neural activity and correlation with evoked-brain potentials in first-episode, treatment-naïve patients with deficit and non-deficit schizophrenia. <b>2017</b> , 261, 9-19		18
242	Effectiveness, efficiency and efficacy in the multidimensional treatment of schizophrenia: Rethinking project. <i>Revista De Psiquiatria Y Salud Mental</i> , <b>2017</b> , 10, 4-20	2.7	11
241	The current conceptualization of negative symptoms in schizophrenia. <b>2017</b> , 16, 14-24		224
240	The course of negative symptoms in first-episode schizophrenia and its predictors: A prospective two-year follow-up study. <i>Schizophrenia Research</i> , <b>2017</b> , 189, 84-90	3.6	30
239	Physio-somatic symptoms in schizophrenia: association with depression, anxiety, neurocognitive deficits and the tryptophan catabolite pathway. <b>2017</b> , 32, 1003-1016		19
238	Responding to challenges for people with psychotic illness: Updated evidence from the Survey of High Impact Psychosis. <i>Australian and New Zealand Journal of Psychiatry</i> , <b>2017</b> , 51, 124-140	2.6	53
237	Comparing EEG Nonlinearity in Deficit and Nondeficit Schizophrenia Patients: Preliminary Data. <b>2017</b> , 48, 376-382		10
236	Primary, Enduring Negative Symptoms: An Update on Research. <i>Schizophrenia Bulletin</i> , <b>2017</b> , 43, 730-736	3.3	55
235	Brain neurodevelopmental markers related to the deficit subtype of schizophrenia. <b>2017</b> , 266, 10-18		13
234	Effectiveness, efficiency and efficacy in the multidimensional treatment of schizophrenia: Rethinking project. <i>Revista De Psiquiatria Y Salud Mental (English Edition)</i> , <b>2017</b> , 10, 4-20	0.2	
233	The impact of current cannabis use on general cognitive function in people with psychotic illness. <i>Schizophrenia Research</i> , <b>2017</b> , 190, 164-171	3.6	6

232	Categorizing and assessing negative symptoms. <b>2017</b> , 30, 201-208		20
231	Negative Symptom Therapeutics. <i>Schizophrenia Bulletin</i> , <b>2017</b> , 43, 681-682	1.3	21
230	Men and women with psychosis and the impact of illness-duration on sex-differences: The second Australian national survey of psychosis. <i>Psychiatry Research</i> , <b>2017</b> , 256, 130-143	9.9	9
229	Confirmatory factor analysis of the quality of life scale and new proposed factor structure for the quality of life scale-revised. <i>Schizophrenia Research</i> , <b>2017</b> , 181, 117-123	3.6	12
228	Structural brain changes are associated with response of negative symptoms to prefrontal repetitive transcranial magnetic stimulation in patients with schizophrenia. <b>2017</b> , 22, 857-864		33
227	Clozapine users in Australia: their characteristics and experiences of care based on data from the 2010 National Survey of High Impact Psychosis. <b>2017</b> , 26, 325-337		16
226	Neuropsychological Profile of Specific Executive Dysfunctions in Patients with Deficit and Non-deficit Schizophrenia. <b>2017</b> , 8, 1459		11
225	A New Division of Schizophrenia Revealed Expanded Bilateral Brain Structural Abnormalities of the Association Cortices. <i>Frontiers in Psychiatry</i> , <b>2017</b> , 8, 127	5	1
224	Social Dysfunction and Diet Outcomes in People with Psychosis. <b>2017</b> , 9,		9
223	The negative symptoms of schizophrenia primary and secondary, deficit syndrome, persistent negative symptoms. <b>2017</b> , 12, 108-117		
222	Impaired reward responsiveness in schizophrenia. <i>Schizophrenia Research</i> , <b>2018</b> , 199, 46-52	3.6	5
221	Functional connectivity of the ventral tegmental area and avolition in subjects with schizophrenia: a resting state functional MRI study. <b>2018</b> , 28, 589-602		14
220	Neurocognitive functioning and quality of life in patients with and without deficit syndrome of schizophrenia. <i>Psychiatry Research</i> , <b>2018</b> , 263, 54-60	9.9	12
219	Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , <b>2018</b> , 268, 625-639	5.1	86
218	In Schizophrenia, Depression, Anxiety, and Physiosomatic Symptoms Are Strongly Related to Psychotic Symptoms and Excitation, Impairments in Episodic Memory, and Increased Production of Neurotoxic Tryptophan Catabolites: a Multivariate and Machine Learning Study. <b>2018</b> , 33, 641-655		30
217	An investigation into the drivers of avolition in schizophrenia. <i>Psychiatry Research</i> , <b>2018</b> , 261, 225-231	9.9	1
216	The brief negative symptom scale (BNSS): Sensitivity to treatment effects. <i>Schizophrenia Research</i> , <b>2018</b> , 197, 269-273	3.6	12
215	Negative symptoms of schizophrenia: new developments and unanswered research questions. <b>2018</b> , 5, 664-677		159

214	Deficit schizophrenia is a discrete diagnostic category defined by neuro-immune and neurocognitive features: results of supervised machine learning. <b>2018</b> , 33, 1053-1067		30
213	Deficit, but Not Nondeficit, Schizophrenia Is Characterized by Mucosa-Associated Activation of the Tryptophan Catabolite (TRYCAT) Pathway with Highly Specific Increases in IgA Responses Directed to Picolinic, Xanthurenic, and Quinolinic Acid. <b>2018</b> , 55, 1524-1536		28
212	Attacking Heterogeneity in Schizophrenia by Deriving Clinical Subgroups From Widely Available Symptom Data. <i>Schizophrenia Bulletin</i> , <b>2018</b> , 44, 101-113	1.3	25
211	Deficit Schizophrenia Is Characterized by Defects in IgM-Mediated Responses to Tryptophan Catabolites (TRYCATs): a Paradigm Shift Towards Defects in Natural Self-Regulatory Immune Responses Coupled with Mucosa-Derived TRYCAT Pathway Activation. <b>2018</b> , 55, 2214-2226		24
210	Psychopharmacologic treatment of in-patients with schizophrenia: comparing forensic and general psychiatry. <b>2018</b> , 29, 1-15		3
209	Polymorphisms in immune-inflammatory response genes and the risk of deficit schizophrenia. <i>Schizophrenia Research</i> , <b>2018</b> , 193, 359-363	3.6	8
208	Depressive, anxiety and hypomanic symptoms in schizophrenia may be driven by tryptophan catabolite (TRYCAT) patterning of IgA and IgM responses directed to TRYCATs. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2018</b> , 80, 205-216	5.5	9
207	Negative symptoms of psychosis: A life course approach and implications for prevention and treatment. <b>2018</b> , 12, 561-571		18
206	Apathy in schizophrenia: A review of neuropsychological and neuroanatomical studies. <b>2018</b> , 118, 22-33		27
205	Changes in Tryptophan Catabolite (TRYCAT) Pathway Patterning Are Associated with Mild Impairments in Declarative Memory in Schizophrenia and Deficits in Semantic and Episodic Memory Coupled with Increased False-Memory Creation in Deficit Schizophrenia. <b>2018</b> , 55, 5184-5201		32
204	Prospective Relationships Between Motivation and Functioning in Recovery After a First Episode of Schizophrenia. <i>Schizophrenia Bulletin</i> , <b>2018</b> , 44, 369-377	1.3	22
203	Treating body, treating mind: The experiences of people with psychotic disorders and their general practitioners - Findings from the Australian National Survey of High Impact Psychosis. <i>Australian and New Zealand Journal of Psychiatry</i> , <b>2018</b> , 52, 561-572	2.6	5
202	Avolition-Apathy and White Matter Connectivity in Schizophrenia: Reduced Fractional Anisotropy Between Amygdala and Insular Cortex. <b>2018</b> , 49, 55-65		17
201	The Neural Correlates of Negative Symptoms in Schizophrenia: Examples From MRI Literature. <b>2018</b> , 49, 12-17		5
200	Impact of Reward and Loss Anticipation on Cognitive Control: An Event-Related Potential Study in Subjects With Schizophrenia and Healthy Controls. <b>2018</b> , 49, 46-54		3
199	Schizophrenia heterogeneity revisited: Clinical, cognitive, and psychosocial correlates of statistically-derived negative symptoms subgroups. <b>2018</b> , 97, 8-15		41
198	Neural substrate of unrelenting negative symptoms in schizophrenia: a longitudinal resting-state fMRI study. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , <b>2018</b> , 268, 641-651	5.1	6
197	Negative Symptoms of Schizophrenia: Constructs, Burden, and Management. <b>2018</b> ,		1

196	DNA Methylation and Gene Expression of Matrix Metalloproteinase 9 Gene in Deficit and Non-deficit Schizophrenia. <b>2018</b> , 9, 646		15
195	Potential Role of Antipsychotic-Galantamine-Memantine Combination in the Treatment of Positive, Cognitive, and Negative Symptoms of Schizophrenia. <b>2018</b> , 4, 134-148		17
194	Minocycline as adjunct therapy for a male patient with deficit schizophrenia. <b>2018</b> , 14, 2697-2701		4
193	Patterns of schizophrenia symptoms: hidden structure in the PANSS questionnaire. <b>2018</b> , 8, 237		5
192	Is cannabis a risk factor for suicide attempts in men and women with psychotic illness?. <b>2018</b> , 235, 2275-2285		3
191	Towards a new classification of stable phase schizophrenia into major and simple neuro-cognitive psychosis: Results of unsupervised machine learning analysis. <b>2018</b> , 24, 879-891		24
190	The Brief Negative Symptom Scale: Validation in a multicenter Brazilian study. <b>2018</b> , 85, 42-47		8
189	A positive take on schizophrenia negative symptom scales: Converting scores between the SANS, NSA and SDS. <i>Schizophrenia Research</i> , <b>2018</b> , 201, 113-119	3.6	3
188	Episodic memory and delayed recall are significantly more impaired in younger patients with deficit schizophrenia than in elderly patients with amnesic mild cognitive impairment. <b>2018</b> , 13, e0197004		5
187	More intensive probing increases the detection of social anxiety disorders in schizophrenia. <i>Psychiatry Research</i> , <b>2018</b> , 268, 358-360	9.9	6
186	Health-Related Quality of Life in People Living with Psychotic Illness and Factors Associated with Its Variation. <b>2018</b> , 21, 1002-1009		15
185	Receipt and targeting of evidence-based psychosocial interventions for people living with psychoses: findings from the second Australian national survey of psychosis. <b>2019</b> , 28, 613-629		7
184	Eotaxin, an Endogenous Cognitive Deteriorating Chemokine (ECDC), Is a Major Contributor to Cognitive Decline in Normal People and to Executive, Memory, and Sustained Attention Deficits, Formal Thought Disorders, and Psychopathology in Schizophrenia Patients. <b>2019</b> , 35, 122-138		33
183	Altered brain gyrification in deficit and non-deficit schizophrenia. <b>2019</b> , 49, 573-580		10
182	Affective modulation of target detection in deficit and non-deficit schizophrenia. <i>Schizophrenia Research</i> , <b>2019</b> , 204, 138-145	3.6	1
181	Schizophrenia Phenomenology Revisited: Positive and Negative Symptoms Are Strongly Related Reflective Manifestations of an Underlying Single Trait Indicating Overall Severity of Schizophrenia.. <b>2019</b> ,		
180	An Early Developmental Marker of Deficit versus Nondeficit Schizophrenia. <i>Schizophrenia Bulletin</i> , <b>2019</b> , 45, 1331-1335	1.3	4
179	Reduced mu opioid receptor availability in schizophrenia revealed with [C]-carfentanil positron emission tomographic imaging. <b>2019</b> , 10, 4493		19

- 178 Breakdown of the Paracellular Tight and Adherens Junctions in the Gut and Blood Brain Barrier and Damage to the Vascular Barrier in Patients with Deficit Schizophrenia. **2019**, 36, 306-322 45
- 177 Foreword. **2019**, ix-x
- 176 Cognition and Its Impairment in Schizophrenia and Related Psychotic Disorders. **2019**, 1-17
- 175 Index. **2019**, 179-184
- 174 Preface. **2019**, xi-xii
- 173 Progressive brain structural changes after the first year of treatment in first-episode treatment-naïve patients with deficit or nondeficit schizophrenia. **2019**, 288, 12-20 4
- 172 The Brain That Builds Itself. **2019**, 18-30
- 171 Cognitive Enhancement. **2019**, 31-44
- 170 Getting Ready for Cognitive Enhancement. **2019**, 45-57
- 169 Computer-based Approaches to Cognitive Enhancement. **2019**, 58-71
- 168 Individual and Group Approaches to Cognitive Enhancement. **2019**, 72-89
- 167 Psychopharmacological Approaches, Cognitive Enhancement, and Brain Stimulation. **2019**, 90-102 1
- 166 Who Responds Best? Predictors and Moderators of Cognitive Enhancement. **2019**, 103-114
- 165 Choosing the Right Treatment for the Right Patient. **2019**, 115-127
- 164 Approaches to Assessment and Monitoring Treatment Response. **2019**, 128-137
- 163 Research in Cognitive Enhancement. **2019**, 138-150
- 162 Glossary. **2019**, 151-154
- 161 References. **2019**, 155-178

160	Diagnostic and symptom interviews for adults. <b>2019</b> , 355-393		2
159	Upregulation of the Intestinal Paracellular Pathway with Breakdown of Tight and Adherens Junctions in Deficit Schizophrenia. <b>2019</b> , 56, 7056-7073		25
158	A review of autobiographical memory studies on patients with schizophrenia spectrum disorders. <b>2019</b> , 19, 361		6
157	Schizophrenia phenomenology comprises a bifactorial general severity and a single-group factor, which are differently associated with neurotoxic immune and immune-regulatory pathways. <b>2019</b> , 10, 209-225		16
156	Evoked Potentials Investigations of Deficit Versus Nondeficit Schizophrenia: EEG-MEG Preliminary Data. <b>2019</b> , 50, 75-87		5
155	Supervised machine learning to decipher the complex associations between neuro-immune biomarkers and quality of life in schizophrenia. <b>2019</b> , 34, 267-282		11
154	Schizophrenia is Associated With an Aberrant Immune Response to Epstein-Barr Virus. <i>Schizophrenia Bulletin</i> , <b>2019</b> , 45, 1112-1119	1.3	21
153	In Schizophrenia, Increased Plasma IgM/IgA Responses to Gut Commensal Bacteria Are Associated with Negative Symptoms, Neurocognitive Impairments, and the Deficit Phenotype. <b>2019</b> , 35, 684-698		31
152	In Schizophrenia, Deficits in Natural IgM Isotype Antibodies Including those Directed to Malondialdehyde and Azelaic Acid Strongly Predict Negative Symptoms, Neurocognitive Impairments, and the Deficit Syndrome. <b>2019</b> , 56, 5122-5135		14
151	First-episode schizophrenia is associated with a reduction of HERV-K methylation in peripheral blood. <i>Psychiatry Research</i> , <b>2019</b> , 271, 459-463	9.9	17
150	Neurocognitive functioning in patients with first-episode schizophrenia: results of a prospective 15-year follow-up study. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , <b>2020</b> , 270, 689-698	5.1	8
149	Are Negative Symptoms Merely the "Real World" Consequences of Deficits in Social Cognition?. <i>Schizophrenia Bulletin</i> , <b>2020</b> , 46, 236-241	1.3	23
148	Deficit Versus Nondeficit Schizophrenia: An MEG-EEG Investigation of Resting State and Source Coherence-Preliminary Data. <b>2020</b> , 51, 34-44		6
147	Negative Symptoms and Their Assessment in Schizophrenia and Related Disorders. <b>2020</b> , 153-175		2
146	The Neuroimmune and Neurotoxic Fingerprint of Major Neurocognitive Psychosis or Deficit Schizophrenia: a Supervised Machine Learning Study. <b>2020</b> , 37, 753-771		19
145	Childhood adversity and clinical and psychosocial outcomes in psychosis. <b>2019</b> , 29, e78		13
144	How to Construct a Bottom-Up Nomothetic Network Model and Disclose Novel Nosological Classes by Integrating Risk Resilience and Adverse Outcome Pathways with the Phenome of Schizophrenia. <b>2020</b> , 10,		9
143	Social anhedonia and clinical outcomes in early adulthood: A three-year follow-up study within a community sample. <i>Schizophrenia Research</i> , <b>2020</b> , 223, 213-219	3.6	3



142	Deficit schizophrenia and its features are associated with PON1 Q192R genotypes and lowered paraoxonase 1 (PON1) enzymatic activity: effects on bacterial translocation. <b>2021</b> , 26, 406-415		7
141	Aberrant striatal coupling with default mode and central executive network relates to self-reported avolition and anhedonia in schizophrenia. <b>2020</b> , 145, 263-263		3
140	Lowered Antioxidant Defenses and Increased Oxidative Toxicity Are Hallmarks of Deficit Schizophrenia: a Nomothetic Network Psychiatry Approach. <b>2020</b> , 57, 4578-4597		19
139	A Meta-Analysis of Neuropsychological Effort Test Performance in Psychotic Disorders. <b>2020</b> , 30, 407-424		5
138	Negative symptom configuration within and outside schizophrenia spectrum disorders: results from the "Parma Early Psychosis" program. <i>Psychiatry Research</i> , <b>2020</b> , 294, 113519	9.9	2
137	Neuroanatomy of Patients with Deficit Schizophrenia: An Exploratory Quantitative Meta-Analysis of Structural Neuroimaging Studies. <b>2020</b> , 17,		4
136	Mental health recovery and physical health outcomes in psychotic illness: Longitudinal data from the Western Australian survey of high impact psychosis catchments. <i>Australian and New Zealand Journal of Psychiatry</i> , <b>2021</b> , 55, 711-728	2.6	1
135	EEG Source Network for the Diagnosis of Schizophrenia and the Identification of Subtypes Based on Symptom Severity-A Machine Learning Approach. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	4
134	Schizophrenia phenomenology revisited: positive and negative symptoms are strongly related reflective manifestations of an underlying single trait indicating overall severity of schizophrenia. <b>2021</b> , 26, 368-377		12
133	Chronic fatigue and fibromyalgia symptoms are key components of deficit schizophrenia and are strongly associated with activated immune-inflammatory pathways. <i>Schizophrenia Research</i> , <b>2020</b> , 222, 342-353	3.6	5
132	Characterization of deficit schizophrenia and reliability of the bidimensional model of its negative symptomatology. <b>2020</b> , 74, 400-406		2
131	Lifetime psychopathological characteristics associated with comorbid obsessive-compulsive disorder in clinically stable patients with chronic schizophrenia. <i>Asian Journal of Psychiatry</i> , <b>2020</b> , 50, 101991	6.7	5
130	Association between DRD2 and ANKK1 polymorphisms with the deficit syndrome in schizophrenia. <b>2020</b> , 19, 39		2
129	In schizophrenia, psychomotor retardation is associated with executive and memory impairments, negative and psychotic symptoms, neurotoxic immune products and lower natural IgM to malondialdehyde. <b>2020</b> , 21, 383-401		11
128	Increased Levels of Plasma Tumor Necrosis Factor- $\alpha$ Mediate Schizophrenia Symptom Dimensions and Neurocognitive Impairments and Are Inversely Associated with Natural IgM Directed to Malondialdehyde and Paraoxonase 1 Activity. <b>2020</b> , 57, 2333-2345		18
127	The gut-microbiome as a target for the treatment of schizophrenia: A systematic review and meta-analysis of randomised controlled trials of add-on strategies. <i>Schizophrenia Research</i> , <b>2021</b> , 234, 1-13	3.6	10
126	Digital phenotyping of negative symptoms: the relationship to clinician ratings. <i>Schizophrenia Bulletin</i> , <b>2021</b> , 47, 44-53	1.3	14
125	Factor Structure, Convergent, and Divergent Validity of the Prodromal Questionnaire-Negative Symptom Subscale. <b>2021</b> , 28, 153-168		3



124	From Memories of Past Experiences to Present Motivation? A Meta-analysis on the Association Between Episodic Memory and Negative Symptoms in People With Psychosis. <i>Schizophrenia Bulletin</i> , 2021,	1.3	2
123	Human-specific cognition. 2021, 61-74		
122	Effects of Oxytocin on Emotion Recognition in Schizophrenia: A Randomized Double-Blind Pilot Study. 2021, 41, 103-113		1
121	Prospective Long-Term Cohort Study of Subjects With First-Episode Psychosis Examining Eight Major Outcome Domains and Their Predictors: Study Protocol. <i>Frontiers in Psychiatry</i> , 2021, 12, 643112	5	1
120	Usability of a Psychotherapeutic Interactive Gaming Tool Used in Facial Emotion Recognition for People with Schizophrenia. 2021, 11,		
119	Inflammatory and Oxidative Pathways Are New Drug Targets in Multiple Episode Schizophrenia and Leaky Gut, Klebsiella pneumoniae, and C1q Immune Complexes Are Additional Drug Targets in First Episode Schizophrenia. 2021, 58, 3319-3334		6
118	White Matter Neurometabolic Signatures Support the Deficit and Nondeficit Distinction in Antipsychotic-Naïve First-Episode Psychosis Patients. <i>Schizophrenia Bulletin</i> , 2021, 47, 1068-1076	1.3	0
117	In (deficit) schizophrenia, a general cognitive decline (G-CoDe) partly mediates the effects of neuro-immune and neuro-oxidative toxicity on the symptomatome and quality of life.		
116	Early versus late risk factors for deficit and nondeficit schizophrenia. <i>Revista De Psiquiatria Y Salud Mental</i> , 2021,	2.7	0
115	In (deficit) schizophrenia, a general cognitive decline partly mediates the effects of neuro-immune and neuro-oxidative toxicity on the symptomatome and quality of life. 2021, 1-10		2
114	Lowered serum cesium levels in schizophrenia: association with immune-inflammatory biomarkers and cognitive impairments. 2021, 43, 131-137		2
113	Primary Negative Symptoms: Refining the Research Target. <i>Schizophrenia Bulletin</i> , 2021, 47, 1207-1210	1.3	2
112	Proposing a causal pathway for health-related quality of life in people with psychotic disorders. 2021, 138, 550-559		2
111	A longitudinal study of lateral ventricle volumes in deficit and non-deficit schizophrenia. 2021, 313, 111311		1
110	Characteristics of people on community treatment orders in Australia: Data from the 2010 National Survey of High Impact Psychosis. <i>Australian and New Zealand Journal of Psychiatry</i> , 2021, 48674211036032	3.6	0
109	The continuity of effect of schizophrenia polygenic risk score and patterns of cannabis use on transdiagnostic symptom dimensions at first-episode psychosis: findings from the EU-GEI study. 2021, 11, 423		1
108	Validity and reliability of the Vigour Assessment Scale in avolitional schizophrenia outpatients. <i>Schizophrenia Research</i> , 2021, 235, 36-43	3.6	0
107	How far to go in deconstructing negative symptoms? Behavioural and neural level evidence for the amotivation domain. <i>Schizophrenia Research</i> , 2021, 236, 41-47	3.6	1

106	On the relation of white matter brain abnormalities and the asociality symptoms in schizophrenia outpatients - a DTI study. <b>2021</b> , 81, 80-95		1
105	EPA guidance on assessment of negative symptoms in schizophrenia. <b>2021</b> , 64, e23		28
104	The Schizophrenia Construct: Symptomatic Presentation. 09-23		7
103	Course and Outcome. 104-141		8
102	Neuroimaging: Diagnostic Boundaries and Biomarkers. <b>2019</b> , 1-56		1
101	Schizophrenie Psychosen. <b>2011</b> , 1420-1529		3
100	Psychopathologie heute. <b>1999</b> , 3-44		3
99	Negative Symptoms: A Critique of Current Approaches. <b>1991</b> , 126-133		8
98	Neuropsychology and neurophysiology in schizophrenia. <b>1996</b> , 9, 57-62		13
97	Failure of fusion of the septum pellucidum and the heterogeneity of schizophrenia. <b>1997</b> , 185, 639-41		5
96	Insight and interpersonal function in schizophrenia. <b>1998</b> , 186, 432-6		115
95	A new schizophrenia model: immune activation is associated with induction of the tryptophan catabolite pathway and increased eotaxin levels which together determine memory impairments and schizophrenia symptom dimensions.		2
94	D-serine added to clozapine for the treatment of schizophrenia. <i>American Journal of Psychiatry</i> , <b>1999</b> , 156, 1822-5	11.9	154
93	Empirical validation of primary negative symptoms: independence from effects of medication and psychosis. <i>American Journal of Psychiatry</i> , <b>1999</b> , 156, 406-11	11.9	71
92	Neurocognitive Impairments in Deficit and Non-Deficit Schizophrenia and Their Relationships with Symptom Dimensions and Other Clinical Variables. <b>2015</b> , 10, e0138357		31
91	[Controversial problems of clinical psychiatry]. <i>Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova</i> , <b>2014</b> , 114, 8-11	0.4	2
90	[Personality disorders and schizophrenic defect (problem of comorbidity)]. <i>Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova</i> , <b>2018</b> , 118, 4-14	0.4	5
89	Construction of a Neuro-Immune-Cognitive Pathway-Phenotype Underpinning the Phenome of Deficit Schizophrenia. <b>2020</b> , 20, 747-758		12

88	Neural Basis of Anhedonia and Amotivation in Patients with Schizophrenia: The Role of Reward System. <b>2015</b> , 13, 750-9		34
87	A New Schizophrenia Model: Immune Activation is Associated with the Induction of Different Neurotoxic Products which Together Determine Memory Impairments and Schizophrenia Symptom Dimensions. <b>2019</b> , 18, 124-140		25
86	Inflammation and Oxidative Stress in Deficit Schizophrenia. <b>2020</b> , 57, 303-307		2
85	Minocycline for negative symptoms of schizophrenia and possible mechanistic actions: the BeneMin RCT. <b>2019</b> , 6, 1-66		1
84	The Effects of Olanzapine and Risperidone on Learning and Retaining Entry-Level Work Skills. <b>2009</b> , 3, 133-141		1
83	Obstetrical complications, social class and type of schizophrenia. <b>2011</b> , 5, 33-9		2
82	Deficit schizophrenia: Concept and validity. <b>2008</b> , 50, 61-6		8
81	Negative symptoms in schizophrenia. <i>Industrial Psychiatry</i> , <b>2016</b> , 25, 135-144	0.9	22
80	Is the Prevalence of the Deficit Syndrome in Schizophrenia Higher than Estimated? Results of a Meta-Analysis. <i>Psychiatry Investigation</i> , <b>2018</b> , 15, 94-98	3.1	7
79	Aberrant large-scale brain modules in deficit and non-deficit schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2022</b> , 113, 110461	5.5	0
78	Symptome schizophrener Störungen. <b>2000</b> , 3-51		2
77	Frecuencia de la apolipoproteína E-e4, en la esquizofrenia de déficit. <i>European Psychiatry (Ed Española)</i> , <b>2000</b> , 7, 41-44		
76	Mes de nacimiento en pacientes esquizofrénicos con y sin déficit. <i>European Psychiatry (Ed Española)</i> , <b>2000</b> , 7, 193-195		
75	Symptoms of Schizophrenia. <b>2001</b> , 1373-1406		
74	Long-Term Olanzapine Treatment in Schizophrenic Outpatients: Its Effects on Their Quality of Life and Clinical Outcome. <b>2002</b> , 132-145		
73	Patrones cognitivos en los subtipos de la esquizofrenia. <i>European Psychiatry (Ed Española)</i> , <b>2002</b> , 9, 449-457		
72	Zurdera en los subtipos de esquizofrenia. <i>European Psychiatry (Ed Española)</i> , <b>2003</b> , 10, 107-112		
71	El síndrome deficitario en la esquizofrenia: implicaciones para el tratamiento de los síntomas negativos. <i>European Psychiatry (Ed Española)</i> , <b>2004</b> , 11, 219-224		

- 70 Calidad de vida en esquizofrnicos con y sin el sndrome de dficit. *European Psychiatry (Ed Espaola)*, **2004**, 11, 374-377
- 69 La calidad subjetiva de vida en pacientes esquizofrnicos de dficit y no de dficit. *European Psychiatry (Ed Espaola)*, **2005**, 12, 454-456
- 68 Psychotic Behavior. **2006**, 349-370
- 67 Un anlisis preliminar del subtipo esquizofrnico, la estacionalidad del nacimiento y la clase social. *European Psychiatry (Ed Espaola)*, **2007**, 14, 297-303
- 66 Evaluaci3n clnica de los sntomas negativos de la esquizofrenia. *European Psychiatry (Ed Espaola)*, **2007**, 14, 375-382
- 65 Diagnostic Rating Scales and Psychiatric Instruments. **2008**, 79-90
- 64 Schizophrene Psychosen. **2008**, 1255-1358
- 63 Evaluation of symptomatology on schizophrenia. *Medical Psychiatry*, **2009**, 32-38
- 62 Efficacy of Novel Antipsychotic Drugs in Treatment-Refractory Schizophrenia. *Handbook of Experimental Pharmacology*, **2010**, 333-357 3.2
- 61 Kognitive Stfungen bei schizophrenen Erkrankungen im Verlauf: Ergebnisse einer 5-Jahres-Katamnese. **2010**, 177-184
- 60 Negative Symptoms Across the Schizophrenia Spectrum: Phenomenological and Neurobiological Perspectives. **2011**, 1-32
- 59 Formas deficitria e n3o deficitria da esquizofrenia n3o diferem quanto sazonalidade de nascimentos nas regi3es Sul e Sudeste do Brasil. *Jornal Brasileiro De Psiquiatria*, **2011**, 60, 337-340 0.5
- 58 Bibliographie. **2012**, 151-167
- 57 Positive and Negative Symptomatology: The State of Affairs. **1991**, 441-460 1
- 56 Assessment of Negative Symptoms: Instruments and Evaluation Criteria. **1991**, 52-70 3
- 55 Patterns of Clinical Efficacy for Antipsychotic Drugs. *Handbook of Experimental Pharmacology*, **1996**, 313-331
- 54 Primre Negativsymptomatik und Verlauf psychiatrischer Stfungen. **1996**, 329-332
- 53 Die retrospektive Erfassung der Negativsymptomatik im Fr3uverlauf der Schizophrenie. **1997**, 13-29

52	Die deutsche Übersetzung der Carpenter-Kriterien für das Defizitsyndrom (primäre überdauernde Negativsymptomatik). <b>1997</b> , 45-47		1
51	Historia familiar y forma de déficit en esquizofrenia. <i>European Psychiatry (Ed Española)</i> , <b>1997</b> , 4, 121-123		
50	Bedeutung der primären Minussymptomatik bei der Therapie mit Neuroleptika. <b>1998</b> , 121-133		
49	Atypische Neuroleptika: Ein neuer Ansatz in der Behandlung negativer Symptome?. <b>1999</b> , 25-41		
48	Assessing Psychosis in African American Clients. <b>2015</b> , 247-259		3
47	References. <b>2015</b> , 165-183		
46	[A history and overview of anhedonia in endogenous mental disorders]. <i>Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova</i> , <b>2017</b> , 117, 96-101		0.4
45	Supervised machine learning to decipher the complex associations between neuro-immune biomarkers and quality of life in schizophrenia.		
44	Cognitive Enhancement in Schizophrenia and Related Disorders. <b>2019</b> ,		1
43	Schizophrenia polygenic risk score and cannabis use modify psychosis expression in first episode psychosis patients and population controls.		
42	Cultural Considerations for Schizophrenia Spectrum Disorders Part I: Symptoms, Diagnosis, and Prevalence. <b>2020</b> , 363-380		
41	Clinical symptoms and social functioning in schizophrenia. <i>Revista De Psiquiatria Y Salud Mental</i> , <b>2020</b> ,		2.7
40	Plasma nitrate levels in deficit versus non-deficit forms of schizophrenia. <i>Journal of Psychiatry and Neuroscience</i> , <b>2003</b> , 28, 288-92	4.5	25
39	Negative symptoms in nondeficit syndrome respond to neuroleptic treatment with changes in plasma homovanillic acid concentrations. <i>Journal of Psychiatry and Neuroscience</i> , <b>1996</b> , 21, 167-71	4.5	3
38	Negative symptom configuration in patients with first episode affective psychosis: findings from the 1-year follow-up of the "Parma Early Psychosis" program. <i>Acta Biomedica</i> , <b>2021</b> , 92, e2021224	3.2	
37	Eye movement characteristics in male patients with deficit and non-deficit schizophrenia and their relationships with psychiatric symptoms and cognitive function. <i>BMC Neuroscience</i> , <b>2021</b> , 22, 70	3.2	0
36	Corpus callosum in schizophrenia with deficit and non-deficit syndrome: a statistical shape analysis.. <i>Annals of General Psychiatry</i> , <b>2021</b> , 34, e100635	5.3	
35	Serum BDNF levels, glycolipid metabolism in deficit schizophrenia: A case-control study.. <i>Asian Journal of Psychiatry</i> , <b>2022</b> , 69, 103003	6.7	0

34	European Validation of the Self-Evaluation of Negative Symptoms (SNS): A Large Multinational and Multicenter Study.. <i>Frontiers in Psychiatry</i> , <b>2022</b> , 13, 826465	5	3
33	Negative symptoms in first episode schizophrenia: treatment response across the 2-year follow-up of the "Parma Early Psychosis" program.. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , <b>2022</b> , 1	5.1	0
32	Health-related quality of life in people with psychotic disorders: The role of loneliness and its contributors.. <i>Australian and New Zealand Journal of Psychiatry</i> , <b>2022</b> , 48674211072437	2.6	
31	Primary and Secondary Negative Symptoms in Schizophrenia.. <i>Frontiers in Psychiatry</i> , <b>2021</b> , 12, 766692	5	6
30	The Deficit Schizophrenia Subtype Is Associated with Low Adherence to the Mediterranean Diet: Findings from a Case-Control Study.. <i>Journal of Clinical Medicine</i> , <b>2022</b> , 11,	5.1	1
29	The factor structure and clinical utility of clinician-rated dimensions of psychosis symptom severity in patients with recent-onset psychosis: Results of a 1-year longitudinal follow-up prospective cohort study.. <i>Psychiatry Research</i> , <b>2022</b> , 310, 114420	9.9	
28	Stability of the diagnosis of deficit syndrome in schizophrenia. <i>American Journal of Psychiatry</i> , <b>1999</b> , 156, 637-9	11.9	51
27	Negative Symptoms: A Brief Story and Advances in Spain.. <i>Revista De Psiquiatría Y Salud Mental (English Edition)</i> , <b>2022</b> , 15, 1-2	0.2	
26	Early versus late risk factors for deficit and nondeficit schizophrenia.. <i>Revista De Psiquiatría Y Salud Mental (English Edition)</i> , <b>2022</b> , 15, 38-46	0.2	0
25	Negative Symptoms: A Brief Story and Advances in Spain. <i>Revista De Psiquiatría Y Salud Mental</i> , <b>2022</b> , 15, 1-2	2.7	0
24	Recognizing Psychosis in Autism Spectrum Disorder.. <i>Frontiers in Psychiatry</i> , <b>2022</b> , 13, 768586	5	1
23	The interleukin-6/interleukin-23/Thelper-17-axis as a driver of neuro-immune toxicity in the major neurocognitive psychosis or deficit schizophrenia: a precision nomothetic psychiatry analysis.		0
22	Investigating the Relationship between White Matter Connectivity and Motivational Circuits in Subjects with Deficit Schizophrenia: A Diffusion Tensor Imaging (DTI) Study.. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 11,	5.1	1
21	Relationship of awareness of dyskinesia in schizophrenia to insight into mental illness. <i>American Journal of Psychiatry</i> , <b>1999</b> , 156, 1097-9	11.9	28
20	In schizophrenia, the effects of the IL-6/IL-23/Th17 axis on health-related quality of life and disabilities are partly mediated by generalized cognitive decline and the symptomatome.		0
19	Risk factors of deficit and non-deficit schizophrenia: Results from a cross-sectional study. <i>Revista De Psiquiatría Y Salud Mental</i> , <b>2022</b> ,	2.7	0
18	Different Heschlâ€™s Gyrus Duplication Patterns in Deficit and Non-deficit Subtypes of Schizophrenia. <i>Frontiers in Psychiatry</i> , 13,	5	0
17	Association of empathy with clinical symptoms and cognitive function in Chinese chronic schizophrenia patients with and without deficit syndrome. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2022</b> , 119, 110592	5.5	1

16	Updated perspectives on the clinical significance of negative symptoms in patients with schizophrenia. <i>Expert Review of Neurotherapeutics</i> , 1-15	4.3	○
15	Gender Differences in the Psychopharmacological Treatment of Forensic In-Patients With Schizophrenia. <i>Frontiers in Psychiatry</i> , 13,	5	
14	Cluster analysis of negative symptoms identifies distinct negative symptom subgroups. <i>Schizophrenia Research</i> , <b>2022</b> , 246, 207-215	3.6	○
13	Contrasting Frontoparietal Network Connectivity in Antipsychotic Medication-Naive First-Episode Psychosis Patients Who Do and Do Not Display Features of the Deficit Syndrome. <i>Schizophrenia Bulletin</i> ,	1.3	
12	Primary and secondary negative disorders in schizophrenia as an actual problem of modern clinical psychiatry. <b>2022</b> , 122, 41		○
11	The interleukin-6/interleukin-23/T helper 17-axis as a driver of neuro-immune toxicity in the major neurocognitive psychosis or deficit schizophrenia: A precision nomothetic psychiatry analysis. <b>2022</b> , 17, e0275839		○
10	Assessment of Cardiometabolic Risk Reveals Elevated C-Reactive Protein Levels in Patients with Deficit Schizophrenia after Adjustment for Lifestyle Characteristics. <b>2022</b> , 12, 10915		○
9	The relationship between human development and prevalence of deficit schizophrenia: Results from a systematic review and meta-analysis. <b>2022</b> , 317, 114910		○
8	Primary and secondary negative symptoms severity and the use of psychiatric care resources in schizophrenia spectrum disorders: A 3-year follow-up longitudinal retrospective study. <b>2022</b> , 250, 31-38		2
7	Deficit Symptomatology of Schizophrenia Is Associated with Attenuated Taste Identification: Findings from a Cross-Sectional Study. <b>2022</b> , 12, 1520		○
6	Risk factors of deficit and non-deficit schizophrenia: Results from a cross-sectional study. <b>2022</b> , 15, 223-229		○
5	Clinical symptoms and social functioning in schizophrenia. <b>2022</b> , 15, 251-258		○
4	In Schizophrenia, the Effects of the IL-6/IL-23/Th17 Axis on Health-Related Quality of Life and Disabilities Are Partly Mediated by Generalized Cognitive Decline and the Symptomatology. <b>2022</b> , 19, 15281		○
3	Importance of the dysregulation of the kynurenine pathway on cognition in schizophrenia: a systematic review of clinical studies.		○
2	The deficit subtype of schizophrenia is associated with a pro-inflammatory phenotype but not with altered levels of zonulin: Findings from a case-control study. <b>2023</b> , 153, 106109		○
1	Discontinuing cannabis use: Symptomatic and functional outcomes in people with an established psychotic disorder. <b>2023</b> , 254, 118-124		○